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Abstract 
Malignant melanoma is one of the most devastating cancer types with aggressive metastasizing 
abilities and the capability to develop therapy resistance. Until recently, effective therapeutic options 
have been non-existing, but in 2011/2012 the mutated BRAF inhibitor vemurafenib/Zelboraf® was 
approved by the FDA and EU, showing improved overall survival compared to existing therapy. 
Unfortunately, the effects of the drug are short-lived and new strategies to overcome resistance are 
under intense investigation. 
 
In the present work, combination therapy with vemurafenib and the TRAIL receptor agonist APG350 
has been evaluated in 2D- and 3D-cultures of the melanoma cell lines Melmet 1 and Melmet 5. It was 
observed that combination of the two drugs induces synergistic effects compared to mono-therapy in 
both cell lines, but synergy was dependent on the culturing type and drug dose utilized. In Melmet 5, 
synergistic results were obtained in 2D-cultures, 3D-cultures and the PuMA-assay, although the latter 
was not fully optimized at the time of study and the results are therefore not conclusive. In Melmet 1, 
most of the concentrations tested in 2D-cultures indicated antagonistic effects, while synergy was 
obtained in 3D cultures using the same concentrations. Western analysis of both cell lines showed 
increased cleavage of caspase-9, caspase-3 and PARP as well as upregulation of Bim and 
downregulation of Mcl-1, suggesting enhanced activation of apoptotic pathways. 
 
The melanoma cells’ disposition for metastasizing and therapy resistance do not solely arise from 
intrinsic properties of the cell but are linked to tumor interactions with the microenvironment (TME), 
e.g. stromal cells, soluble molecules and extracellular matrix components. Thus components of TME 
should be taken into account when screening for new therapies, and conditioned medium from WI-38 
lung fibroblasts and co-cultures were used to evaluate the impact of TME-effects on drug response. 
WI-38 cells affected the melanoma cells response to therapy by inducing decreased effect of 
vemurafenib and increased effect of APG350. The results also indicated that fibroblast secreted factors 
for the most part were responsible for the change in drug effect, but that direct cell-cell contact can 
contribute to change these effects. 
 
Overall the results imply that combination therapy of APG350 and vemurafenib may be effective as a 
new therapeutic strategy for melanoma patients, but further studies on TME effects and validation of 
the results in additional cell lines and in in vivo models are needed.  
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Sammendrag 
Malignt melanom er en av de mest alvorlige krefttypene med aggressive metastaserende egenskaper 
og med evne til å utvikle resistens mot terapi. Inntil nylig har effektive legemidler mot sykdommen 
vært ikke-eksisterende, men i 2011/2012 ble vemurafenib/Zelboraf®, en mutert BRAF-inhibitor som 
viser økt total overlevelse sammenlignet med eksisterende behandling, godkjent av både FDA og EU. 
Dessverre er effekten av legemiddelet kortvarig, og nye strategier for å overkomme resistens er under 
intens forskning.  
 
I det gjeldende arbeidet har kombinasjonsbehandling med legemiddelet vemurafenib og TRAIL-
reseptor agonisten APG350 blitt evaluert i 2D- og 3D-kulturer med melanom cellelinjene Melmet 1 og 
Melmet 5. Det ble observert at kombinasjon av de to medikamentene gir synergistiske effekter i 
forhold til monoterapi i begge cellelinjer, men synergi var avhengig av dyrkningsformen og 
medikamentdose. I Melmet 5 ble synergistiske resultater oppnådd ved bruk av 2D-kulturer, 3D-
kulturer og PuMA, men sistenevnte var ikke fullt ut optimalisert ved undersøkelsestidspunktet og er 
derfor ikke konkluderende. I Melmet 1 ga de fleste testede medikamentkonsentrasjonene 
antagonistiske effekter i 2D-kulturer, mens 3D-kulturer viste synergi med de samme konsentrasjonene. 
Western analyser av begge cellelinjer viste økt kløyving av caspase-9, caspase-3 og PARP, i tillegg til 
oppregulering av Bim og nedregulering av Mcl-1, noe som tyder på økt aktivering av apoptotiske 
signalveier. 
 
Melanomcellers evne til metastasering og utvikling av terapiresistens oppstår ikke kun utifra indre 
egenskaper hos cellene, men er knyttet til interaksjoner med tumor mikromiljøet (TME) gjennom 
f.eks. stromale celler, løselige molekyler og ekstracellulære matriks-komponenter. Dermed bør man ta 
hensyn til TME ved screening av nye virkestoffer, og kondisjonert medium fra WI-38 
lungefibroblaster og ko-kulturer ble brukt til å evaluere effekten av TME på medikamentrespons. WI-
38 celler påvirket melanomcellenes terapirespons ved å gi redusert virkning av vemurafenib og økt 
virkning av APG350. Resultatene antydet i tillegg at faktorer sekrert av fibroblaster hovedsakelig var 
ansvarlig for endringen i medikamenteffekt, men at direkte celle-cellekontakt kan bidra til å forandre 
disse effektene. 
 
Alt i alt antyder resultatene at kombinasjonsbehandling med APG350 og vemurafenib kan være 
effektiv som en ny terapeutisk strategi for melanom pasienter, men flere studier på TME-effekter og 
validering av resultatene i flere cellelinjer og i in vivo-modeller er nødvendig.  
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1. Introduction 
1.1 Malignant melanoma 
Malignant melanoma of the skin is considered to be one of the most aggressive types of all human 
cancers and is the most deadly type of skin cancer1. The Cancer Registry of Norway states that 
malignant melanoma was one of two cancer types with the strongest increase in incident rates in 
Norway in 2010, with 1518 new incidents2. The number of deaths was 3382, making the top 10 list of 
cancer types with the highest death rate in Norway. In addition to this, malignant melanoma affects 
young people in a larger scale than most other solid tumor cancers, thereby giving a dramatic effect in 
terms of years lost.  
 
Malignant melanoma originates in melanocytes, the pigment producing cells predominantly found in 
the skin3. Melanocytes are derived from neural crest cells and are found along the basement membrane 
in the basal layer of the epidermis4. The cells produce the dark pigment melanin which absorbs UV-
light and thereby protects the dermis from UV-radiation5, 6. The transformation of melanocytes to 
tumor cells is a process not altogether understood but is known to involve, among other things, genetic 
sequential alterations, activation of oncogenes, inactivation of tumor suppressor genes and impaired 
DNA-repair4. These may occur due to environmental factors; exposure to UV-radiation being 
especially emphasized as a central part in the pathogenesis of the disease5. UV-radiation causes 
genetic changes, impairs immune function and induces formation of reactive oxygen species (ROS) 
which is DNA damaging6. Over-exposure to sunlight and/or sunbed tanning can therefore dramatically 
increase the risk of developing malignant melanoma7. The risk is also higher for people with fair skin, 
families with a history of melanoma, people with multiple benign or atypical nevi and latitude of 
residence for Caucasian people5, 6. 
 
The classic melanoma progression from a benign nevus to metastasizing tumor cells is shown in figure 
1.1. See chapter 1.1.3 for more information about malignant melanomas ability to metastasize. 
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The prognosis of malignant melanoma is strongly related to the stage at which it is detected. Patients 
diagnosed with primary cutaneous melanoma at an early stage can be treated with surgery and the 
overall survival is high, with a five year survival of 90 %8. However, when the cancer has metastasized 
to other parts of the body, usually the lung, liver or brain, it shows a much more aggressive phenotype 
and the survival rates fall dramatically with a median survival of 6 months and a five year survival of 
only 5-22 %8. The low survival rates are due to the resistance of most metastasized tumors to 
chemotherapy and radiotherapy, leaving few therapeutic options for advanced stages3, 9. Early 
detection of the disease is therefore crucial for a good prognosis. Recently new drugs showing effect 
on overall survival have been approved in Europe and USA, as described in chapter 1.1.2. 
 
1.1.1 BRAF mutations in melanoma 
B-Raf is one of three functional Raf proteins in humans along with A-Raf and C-Raf. The Raf proteins 
are serine threonine kinases that play a role in the regulation of the mitogen-activated protein kinase 
signaling pathway (MAPK-pathway)9. The activation of the pathway is initiated by RAS-GTP binding 
and the resulting RAF/MEK/ERK cascade leads to regulation of cell growth, proliferation and 
differentiation in response to growth factors, cytokines and hormones10. Activated RAS can promote 
dimerization of B-Raf and C-Raf, the cooperation leading to full activation of ERK11, 12. Figure 1.2 
shows a simplified version of the MAPK pathway.  
Figure 1.1: A model of the development and progression of malignant melanoma through several steps. 1: Benign nevi are 
common in the overall population and are restricted to the basal layer of the epidermis. 2: If the nevus develops an atypical 
structure and architecture the nevus may be premalignant and progress to the radial growth phase or it may regress. 3: The 
malignantly transformed melanocytes proliferate radially, but don’t have the ability to metastasize. 4: In the vertical growth 
phase the melanocytes break through the basement membrane and invade the dermis. 5: Metastatic melanoma, where the 
cells dissociate from the primary tumor and spreads to secondary sites. The picture is adapted from Miller and Mihm, 20066. 
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B-Raf is the most frequently mutated protein kinase in human cancers and is found in over 50% of all 
melanomas14, 15. The most common BRAF gene mutation, accounting for more than 80 %9, is a 
substitution of valine to glutamic acid at position 600 (V600E), which can result in a 500-fold 
overactivation of the B-Raf kinase activity10. Also V600K and V600D are common, seen in 16 % and 
3 % of all BRAF mutations9. An overactive BRAF gene will lead to an overactive signaling cascade 
through the MAPK pathway, resulting in excessive cell proliferation. Also, the overactive cascade 
increases melanoma cell survival by regulating the expression of several pro-apoptotic and anti-
apoptotic proteins like Bim, Bad and Mcl-19, 16.  
 
Inhibition of mutated BRAF has been a focus area in melanoma research since 20029 and seems to be 
a strategy with quite large impact, leading to e.g. the development of the drug vemurafenib. 
 
1.1.2 Therapy for malignant melanoma 
Until 2011, only two drugs were approved by the US Food and Drug Administration (FDA) as therapy 
for metastatic melanoma; the anti-neoplastic chemotherapy agent dacarbazine (DTIC) and the 
immune-modulating high dose interleukin 2 (HD IL-2)17. Neither of these drugs increases median 
overall survival and they both have a low response rate. Also HD IL-2 is a highly toxic agent 
associated with severe side effects17, 18. In addition to these therapies, high dose interferon alfa-2b is 
approved for adjuvant therapy of resected high-risk melanoma19. In Norway only DTIC and interferon 
alfa-2b, not HD IL-2, has been approved for use.  
Many experimental drugs have been tested in clinical trials the last 20 years with the hope of 
improving the prognosis of metastatic melanoma, but there has not been much progress until recently. 
Figure 1.2: A schematic presentation of the 
MAPK-pathway. Receptor Tyrosine Kinases 
(RTKs) are activated by mitogen binding to the 
extracellular domain of the receptor. This 
activation leads to Ras-GTP binding and the 
transferring of signals through the pathway by 
phosphorylation of RAF, MEK and ERK. ERK 
modulates gene expression through the regulation 
of transcription factors promoting cell 
proliferation and survival. The figure is adapted 
and modified from Montagut & Settleman 200913. 
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In 2011 the FDA approved two novel drugs; the immune stimulatory agent ipilimumab and the BRAF 
V600E inhibitor vemurafenib. These drugs represent a huge leap in melanoma therapy and are a result 
of our time’s increased understanding of melanoma biology, molecular characteristics and tumor 
immunology. Even though the drugs give a better overall survival than previous drugs and for the most 
part give more manageable toxicities, both therapies have their limitations and continued research is 
necessary to improve their effect.   
1.1.2.1 The mutated BRAF inhibitor vemurafenib 
Vemurafenib, a small molecule inhibitor of the BRAF V600E mutation, gets its name from V600E 
mutated BRAF inhibition and is also known under the name PLX 4032 and Zelboraf®. The drug is 
developed by Plexxikon Inc. and Hoffmann-La Roche for the treatment of late-stage melanoma. The 
drug was in 2011 approved by the FDA and in 2012 also by Health Canada and the European 
Commission20. 
 
Vemurafenib is specific against mutant BRAF V600E and V600K. It selectively binds BRAF-
monomers and inhibits their activity, thereby preventing phosphorylation of MEK and ERK i.e. 
inhibiting activation of the MAPK pathway. An indirect apoptotic response with increased Bim 
expression, downregulation of Mcl-1 and dephosphorylation of Bad has also been observed with MEK 
and ERK inhibitors9, 16, 21. The response in patients with the selected mutations has been very 
convincing. The phase I clinical trial showed significant tumor regression in 81 % of the BRAFV600E 
metastatic melanoma patients18. The 1-year survival was shown to be ~50 % and the 2-year survival to 
be 38 % with a median overall survival (OS) of 13,8 months9. The phase II trial (BRIM-2) showed a 
52 % response rate and progression free survival (PFS) of 6,2 months17. The phase III trial (BRIM-3) 
was a randomized trial where metastatic melanoma patients were treated with either vemurafenib or 
dacarbazine. A clear OS benefit was seen in vemurafenib vs. dacarbazine, with a response rate of 48 % 
vs. 5 % and PFS of 5,3 months vs. 1,6 months. Also 84 % vs. 64 % of the patients were alive after 6 
months9, 17. 
 
Despite the good results reported in the clinical trials, the responses to vemurafenib are typically short-
lived with relapse occurring in almost every case. This suggests the existence of intrinsic BRAF 
inhibitor resistance, something that has been documented in preclinical studies9. One resistance 
mechanism recently discovered is a 61-kDa splicing variant of BRAF V600E which lacks the exons 
that encompass the RAS-binding domain11. BRAF lacking this domain are able to dimerize 
independently of RAS signaling, giving a BRAF V600E variant that is resistant to vemurafenib22. 
Acquired resistance after initial response to the drug is also well documented e.g. through gain in 
BRAF V600E copy number, through acute increase in C-Raf and through activating mutations in 
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NRAS23, 24. Additionally, resistance can be achieved through activation of the PI3K-AKT and RAS-C-
Raf-MEK pathways.  
 
Different strategies to overcome resistance have been proposed, for example Thakur et al. (2013)25 has 
shown that drug-resistant cells may display drug dependency, and exploits this by proposing a 
treatment strategy which involves giving pulses of vemurafenib instead of continual treatment. The 
study reveals that intermittent dosing exploits the fitness deficit seen in drug dependent tumor cells in 
the absence of the drug, and the cells remain responsive to vemurafenib25. Another way to overcome 
resistance is combination therapy, a long used strategy that has become even more appealing with the 
development of new targeted drugs. The aim is to target several driver mutations in the tumor 
simultaneously. It has been shown that tumor responses in vemurafenib-treated patients are very 
sensitive to small changes in pathway inhibition14, therefore one can assume that knocking out several 
pathways simultaneously may lead to a greater chance of effect. Also, combination with a drug 
targeted toward the same pathway may prove to be more efficient than vemurafenib alone. For 
instance, combination with drugs targeted towards the PI3K-AKT pathway or inhibitors of MEK can 
be efficient in delaying or preventing relapse23. In addition to these benefits, combination therapy 
could allow drug doses to be lowered, possibly leading to a reduction of side effects. But when 
combining two drugs there is always the possibility that new side-effects develop, which may cause 
worse symptoms than the original mono-therapy. Therefore extensive testing is necessary to be sure 
the combination is safe.  
 
To sum up, the clinical trials of vemurafenib show convincing high response rates and low toxicity, but 
they also reveal less optimistic results showing a relatively short duration of drug effect and a high 
relapse rate. Paradoxically, vemurafenib has also shown an adverse effect on cells with non-mutated 
(wild-type) BRAF26. In wild type cells the drug activates RAF and enhances ERK signaling leading to 
increased proliferation in primary melanoma and increased motility in metastatic melanoma21. 
Ongoing research is therefore necessary to improve the drugs effect and response-duration, and efforts 
should be made to tailor treatments to specific genetic compositions of the tumor.  
 
1.1.3 Influence of the tumor microenvironment (TME) 
One of the hallmarks of malignant melanoma is its high ability to metastasize. This way to invade 
other tissues is a complex process shortly summarized in figure 1.3. Where it earlier was thought that 
the cancer cells ability to metastasize was mostly an intrinsic property of the cell, it is now known that 
the tumor microenvironment plays an important role. Interestingly, this is not a new idea. The “seed 
and soil” hypothesis of Stephen Paget was presented over a century ago in 1889, and suggests that 
tumor cells (the seed) can colonize distant organs (the soil) only where there is a favorable 
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environment for tumor growth27. This theory was however mostly ignored up until recently when TME 
has become a popular area of study. It is now known that tumors can contribute to shaping their own 
microenvironment and that the modifications that occur can support cell proliferation and metastasis.  
 
 
 
The TME consists of supporting connective tissue, the stroma, providing a framework for the tumor29. 
The stroma is built up of non-malignant cells like fibroblasts, endothelial cells, smooth muscle cells 
and bone marrow-derived cells including macrophages and immune cells. These cells can secrete a 
variety of inflammatory-, growth- and survival-factors like cytokines and chemokines, as well as 
extracellular proteases and pro-inflammatory molecules, all of which can enhance a tumors ability for 
survival, growth and invasion throughout the different steps of the metastatic cascade30 (figure 1.3). In 
mammalian tissue a structure called the extracellular matrix (ECM) is also prominent in the cells 
network. The ECM contains among other things collagen, elastin and laminin which give the tissue its 
mechanical properties as well as help organize communication between the cells31. 
The TME not only plays an important role in cancer progression and metastasis, but also in regard to 
drug response. A recent study by Straussman et al.(2012) shows that “anticancer drugs capable of 
Figure 1.3: A schematic presentation summarizing the metastatic process. A) Tumor growth. B) Invasion through the 
endothelial basement membrane, requiring reversible changes in cell-cell and cell-matrix adhesion proteins. C) and D) 
Cells enter the blood and/or lymphatic system where they are transported to secondary sites. The cells have to survive in 
the blood by i.e. avoiding immune recognition. E) Surviving cells can become arrested in capillaries of distant organs 
where they must adhere to the endothelia and extravasate into the tissue. F) Metastatic colonization of the secondary site 
progress through single cells to micrometastasis. Cells can lay dormant for many years before this progression. G) 
Progressively growing tumors and development of a vascular network; angiogenic metastases. Adapted from Steeg 200328. 
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killing tumor cells are rendered ineffective when tumor cells are cultured in the presence of stromal 
cells”32. These findings propose that drug resistance may be caused or partly caused by factors 
secreted by the TME. The same study also identifies HGF as a factor correlated with innate 
(immediate) RAF-inhibitor resistance. HGF induces activation of the receptor tyrosine kinase MET, 
which is reported to be overexpressed in melanoma32. According to Staussman’s study “HGF can 
induce sustained activation of both ERK and AKT (...) predicting that both the MAPK pathway and 
the PI3K-AKT pathway contribute to the primary resistance induced by HGF-secreting stromal 
cells”32. By combining vemurafenib with a c-MET inhibitor one may be able to overcome resistance. 
1.1.3.1 Two-dimensional vs. three-dimensional cultures 
In experimental cell culturing two-dimensional (2D) cultures are commonly used as an initial 
approach to drug screens due to the simplicity of the assays. In 2D-cultures the cells will have 
approximately 50 % of their surface area exposed to hard plastic and have minimal cell-cell and cell-
ECM interactions, which is not comparable to how cells grow in vivo. The 2D-cultures therefore have 
significant limitations in regard to reproducing the complexity and pathophysiology of tumor tissue33. 
Three-dimensional (3D) cultures have proved to be better mimics of how cells grow in vivo, better 
reflecting the TME and cell-cell interactions34. Several 3D-culture systems exist, e.g. whole perfused 
organs, tissue explants and gel/matrix-based cultures, but multicellular tumor spheroids are, according 
to Vinci et.al. (2012), best characterized and most widely used33.  
 
1.2 Apoptosis 
Apoptosis is a highly selective and tightly regulated form of programmed cell death. The term is 
described by Wong (2011) as a situation where “a cell actively pursues a course toward death upon 
receiving certain stimuli”35. The cellular suicide is characterized by cell shrinkage and chromatin 
condensation as well as nuclear fragmentation and cytoskeleton degradation with loss of membrane 
integrity35, 36. Recognition by phagocytic cells before loss of membrane integrity makes apoptosis 
immunologically silent37.  
 
Apoptosis plays an important role in fetal and embryonic development, e.g. in the sculpting of tissue, 
and in adult multicellular organisms where it contributes to tissue remodeling and control of cell 
number and is crucial in the maintenance of homeostasis35-39. But apoptosis is also seen in cells 
exposed to stressful stimuli and cells that have undergone harmful damage. Deregulation of apoptosis 
can lead to various pathologies. The reduced ability to induce apoptosis is linked to uncontrolled cell 
growth, carcinogenesis and autoimmune diseases37. Excessive or inappropriate apoptosis contributes 
to injuries accompanying diseases like Alzheimer’s and stroke39. Targeting different aspects of 
apoptosis is emerging as an important strategy for treatment of cancer35, 39. 
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1.2.1 Caspases and Inhibitors of Apoptosis (IAPs) 
Apoptosis is mainly regulated through two different pathways, the extrinsic and intrinsic pathway, 
both involving cysteine proteases called caspases35. Caspases are the central players in apoptosis, 
cleaving several vital proteins in the cytoskeleton and nuclear scaffold35, 39. Caspases are synthesized 
as inactive monomers, procaspases, and are typically activated by oligomerization following 
proteolytic cleavage by other active caspases or autoproteolysis36, 37. Initiator caspases (caspase-2, -8, -
9, -10) are found at the start of the proteolytic cascade and activate downstream executioner 
procaspases (caspase-3, -6, -7) which again cleave target proteins in the cell. Different cell types can 
be classified as type I and type II cells based on the intrinsic pathways activation status. Type I cells 
activate caspase-3 without involvement of the intrinsic pathway, while type II cells activate both the 
extrinsic and intrinsic pathways through cleavage of Bid, leading to an amplification of the caspase 
cascade40. Figure 1.4 shows and describes the two main apoptotic pathways, both leading to caspase-3 
activation.  
 
Inhibitors of apoptosis are proteins with the ability to bind to and inhibit or degrade activated 
caspases36. X-linked IAP (XIAP) seems to be one of the central players with regard to direct caspase-3 
and 9 blocking41. The intermembrane mitochondrial protein Smac/DIABLO works as an anti-IAP, 
blocking IAPs in the cytosol, and in this way promotes apoptosis. 
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Figure 1.4: An overview of the intrinsic and the extrinsic pathway of apoptosis. The extrinsic pathway is activated by death 
ligands, like TRAIL (chapter 1.2.3) or FAS-ligand, binding to death receptors on the cell surface. An intracellular DISC 
complex is formed which includes the adaptor protein FADD and initiator procaspase-8 or 1036. The DISC brings the 
procaspases into close proximity with each other so they can be activated. The active caspases cleave downstream procaspase-
3 to active caspase-3. The intrinsic pathway is activated by a variety of stresses, like UV-radiation and DNA-damage39. It can 
also be activated through the extrinsic pathway by cleavage of the BH3-only protein Bid to tBid. The pathway is the result of 
increased mitochondrial permeability due to Bax/Bak oligomerization forming pores that release pro-apoptotic molecules like 
cytochrome-c into the cytoplasm (chapter 1.2.2). Cyt-c associates with Apaf-1 and procaspase-9 to form the apoptosome. This 
is a complex that leads to the activation of procaspase-9, which further activates procaspase-3. Both pathways thereby lead to 
the activation of caspase-3 which results in apoptosis. The figure is modified from Zhang (2005)42. 
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1.2.2 The Bcl-2 family of proteins 
The intrinsic pathway of apoptosis is tightly regulated by the Bcl-2 family of proteins36. These proteins 
can be divided into three groups based on their effect on apoptosis; the anti-apoptotic Bcl-2 proteins, 
the pro-apoptotic Bcl-2 proteins and the pro-apoptotic BH3-only proteins, all of which will either 
promote or inhibit the release of cytochrome-c (cyt-c) and other intermembrane mitochondrial proteins 
into the cytosol. The balance between these proteins is more important for apoptosis induction than the 
absolute quantity35. 
 
The Bcl-2 family members are mainly located on the outer mitochondrial membrane. Anti-apoptotic 
proteins, like Bcl-2 itself and Mcl-1 inhibit apoptosis by binding to and inhibiting pro-apoptotic 
proteins like Bax and Bak. In times of cellular stress pro-apoptotic BH3-only proteins, like Bim, Bad 
and Bid, initiate apoptosis by binding to and neutralizing anti-apoptotic proteins. They thereby enable 
Bax and Bak to associate and form a pore, leading to increased mitochondrial permeability and release 
of cyt-c and other mitochondrial proteins into the cytosol36. As described in figure 1.4, cyt-c is 
necessary in the formation of the apoptosome, a complex essential for procaspase 9 activation and 
apoptosis induction35.  
 
Bim is known to be the only BH3-only protein that can bind and inhibit all anti-apoptotic Bcl-2 family 
proteins, and in addition directly bind and activate Bax, thereby making it a potent apoptosis inducer43. 
The pro-apoptotic protein Bad can be phosphorylated at three sites, serine 112, 136 and 155, leading to 
a change in the proteins function resulting in loss of the ability to bind and neutralize anti-apoptotic 
proteins. Phosphorylation of Bad at serine 112 requires activation of the MAPK-pathway, 
phosphorylation of serine 136 is in accordance with Akt-activation, and phosphorylation of serine 155 
follows growth factor stimulation44. 
 
1.2.3 TRAIL induced apoptosis 
TRAIL is the short term for Tumor necrosis factor Related Apoptosis Inducing Ligand. It is a protein 
member of the death receptor (DR) ligand family which is a subclass of the tumor necrosis factor 
(TNF) superfamily45. TRAIL is a type II transmembrane protein normally expressed on the membrane 
of some types of immune cells, as well as human tissues found in e.g. the spleen, prostate and lung46.  
 
TRAIL can activate the extrinsic pathway of apoptosis (figure 1.4) by binding to and activating death 
receptors DR4 and DR5 by receptor trimerization (figure 1.5 A). These receptors contain functional, 
intracellular death domains and can transmit apoptotic signals into the cell. TRAIL can also bind two 
decoy receptors; DcR1 and DcR2, which either lack the death domain (DcR1) or contain a truncated 
death domain (DcR2), making them unable to activate the apoptotic pathway45. Additionally, TRAIL 
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receptors can stimulate non-apoptotic signals like various protein kinase cascades leading to activation 
of e.g. ERK and the transcription factor NFκB, both promoting cell survival47, 48. 
 
Research indicates that TRAIL induces apoptosis mainly in cancer cells, but not in normal tissue46, 49. 
This was early on postulated to be because normal cells mainly express the decoy receptors and are 
found to have lower amounts of death-receptors, making them unable to convey an apoptotic signal 
into the cell45, 49-51. However, it has not been proven that the amount of DcR and functional DR 
correlate with TRAIL sensitivity in cancer cells45. Even so, the specificity towards cancer cells gives 
TRAIL a huge potential as an anticancer agent. Unfortunately there are also challenges related to 
TRAIL, mainly in the form of TRAIL-resistance which can be both inherited and acquired47. Because 
decoy receptors bind TRAIL with the same affinity as the death receptors, they can provoke resistance 
to TRAIL-mediated apoptosis by competing with DR4 and DR546, 47, 50. Complicating things more is 
the issue that approximately one third of melanoma cell lines show resistance to TRAIL even though 
they have high levels of death receptors on their surface49. This can be explained in several ways, for 
example by loss of caspase-8, dysfunctional FADD or caspase-3 inhibition by XIAP48, 49. Because of 
resistance issues it has become apparent that TRAIL agonists as mono-therapy are efficient for only a 
limited number of patients, and combined therapy could therefore be an approach to maximize the 
therapeutic effect of TRAIL45.  
  
Several clinical agents targeting TRAIL have been approved as drugs and even more are under clinical 
testing. Examples include recombinant TRAIL agents, anti-TRAIL receptor antibodies and gene 
therapy agents expressing TRAIL47. Toxicity associated with such therapeutics is low, unlike most 
other anti-cancer drugs. However, studies have shown that tumor cells which are resistant to TRAIL-
induced apoptosis may react to TRAIL treatment with increased growth and metastasis47, 48. This could 
be explained by TRAILs ability to activate other signaling pathways, like the MAPK pathway or 
NFκB, alongside the apoptosis machinery47. It is therefore of vital importance to identify patients with 
TRAIL resistant tumors before treatment with TRAIL receptor targeted drugs.  
1.2.3.1 The TRAIL receptor agonist APG350 
APG350 is a TRAIL receptor agonist developed by Apogenix (Heidelberg, Germany) for the treatment 
of solid tumors. The agent consists of two single chain TRAIL-receptor binding domains dimerized 
via the Fc-part of a human IgG molecule, creating six receptor binding sites per molecule (figure 
1.5B). This enables the compound to bind to and induce trimerization of several TRAIL-receptors 
simultaneously, forming active TRAIL receptor multimers that activate apoptotic signaling. APG350 
only binds to DR4 and DR5, not the decoy receptors. This ability to form multimers, along with it not 
requiring cross-linking via Fcα-receptors, distinguishes APG350 from other TRAIL receptor agonist, 
making it, according to the producer, more efficient in the induction of apoptosis52.  
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Clinical studies of APG350 will be initiated at the earliest in 2015, and the agent will most likely be 
developed in combination with already approved drugs or chemotherapeutics. 
 
 
 
1.3 Other types of cellular death 
The last decade it has become clear that apoptosis is not the only cell death program for removal of 
unwanted cells. Other types of cell death are autophagy, necrosis and pyroptosis. Necrosis is a form of 
cellular death associated with pathological conditions. Traditionally it was considered a passive and 
uncontrolled form of cell death resulting from physical damage, but it has lately become evident that 
in certain conditions necrosis can also be the result of regulated signaling. This caspase-independent 
cell death, often called necroptosis, can be activated by the same ligands as apoptosis. Thus they can 
act as a “back-up” cell death pathway in cells where caspase activation is hampered37. In other words 
necrosis can act as a substitute for apoptosis. In contrast to apoptosis, necrosis will initiate an 
inflammatory response and affect neighboring cells39. 
 
Autophagy is a catabolic pathway that degrades and recycles dysfunctional or unnecessary cellular 
components through the lysosomal machinery, e.g. under times of cellular stress. Autophagy is well-
established as a pro-survival role ensuring intracellular homeostasis, but autophagic activity may also 
accompany and in some cases lead to cell death37. Several connections between autophagy and 
apoptosis and necrosis exists, and it is debatable whether autophagy is a distinct form of cell death or 
if it accompanies or triggers another form of cell death37, 53.   
 
Figure 1.5: A) Illustration of how TRAIL in normal cells bind to TRAIL receptors on the cell surface and induce apoptosis 
by trimerization of the receptors. B) APG350 is a TRAIL receptor agonist that induces clustering of up to six TRAIL 
receptors simultaneously, forming highly active TRAIL receptor multimers. The figure is acquired from Apogenix.com 
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Pyroptosis is a recently recognized form of cell death distinct from necrosis and apoptosis. It is seen in 
cells like macrophages, monocytes and dendritic cells infected with microbial pathogens and is part of 
the host defense system37. Pyroptosis is dependent on caspase-1, a member of the inflammatory 
caspases not involved in apoptosis. It is activated in a complex called the inflammasome, an analogy 
to the apoptosome, and active caspase-1 induces pore formation in the plasma membrane leading to 
water influx, cell swelling and finally cell lysis54. Caspase-1 activation leads to an inflammatory 
response. 
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Aims of the study 
The aim of the present project was to evaluate the effect of combination treatment vs. mono-therapy 
with the mutated BRAF inhibitor vemurafenib and the TRAIL receptor agonist APG350 on malignant 
melanoma cells. Additionally, the impact of tumor microenvironment (TME) interactions on the 
therapy response was investigated with the lung as a model organ and fibroblasts as model cells. 
 
Specific aims: 
 
1) Evaluate the effect of combination therapy with vemurafenib and APG350 compared to mono-
therapy on the cell lines Melmet 1 and Melmet 5 in 2D- and 3D-cultures. 
 
2) Study the expression of apoptotic proteins after treatment with the antitumor drugs through 
Western immunoblotting analysis. 
 
3) Study the impact of the TME on melanoma cells’ response to the antitumor drugs through co-
culture experiments, conditioned medium experiments and the PuMA-assay. 
 
Through these investigations we anticipate to obtain valuable information regarding the impact of the 
TME on drug response in melanoma cell lines and to get an evaluation of the treatment potential of 
combining vemurafenib with APG350. 
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2. Materials and Methods 
In this project Melmet cells were grown in both 2D- and 3D-cultures and treated with vemurafenib 
and/or APG350 to evaluate the cell lines’ general drug response. Additionally, cells were cultured in 
conditioned medium, as co-cultures and in mouse lung tissue. The cells were analyzed with various 
assays to determine the cell viability, and Western immunoblotting was performed to evaluate protein 
expression. Figure 2.1 gives an overview of treatment strategies and methods of analysis for the 
various model systems. Additional information regarding the various setups can be found throughout 
this chapter. A list of reagents and materials used in the experiments are given in Appendix I. 
 
 
2.1 Cell lines  
2.1.1 Melmet cells 
Two melanoma cell lines were used in this study, Melmet 1 and Melmet 5. The Melmet cells represent 
“close-to-patient” early-passage materials and are therefore proposed to be less differentiated than 
commercially available cell lines that have been cultured in vitro55. The cell lines were established at 
the Norwegian Radium Hospital, Department of Tumor Biology, by isolation of cells from metastatic 
melanoma patient biopsies. The procedure was performed using immunomagnetic beads conjugated 
Figure 2.1: An overview of the different culture types, therapy treatments and assays used in this project. 
Materials and Methods 
 28  
  
with melanoma-specific antibody as described by Prasmickaite et al.56. Table 2.1 gives an overview of 
background information regarding the cell lines. 
 
 
 Melmet 1 Melmet 5 
Source 36 year old female 56 year old male 
Tissue (site of biopsies) Subcutaneous Lymph node 
Common sites of metastasis Preference to brain Multiple sites: Brain, lung, 
liver, spinal cord ++ 
Phenotype Invasive 
Low- proliferative 
Proliferative 
Low-invasive 
BRAF-V600E mutation Yes Yes 
Tumorigenic ability in mice  Yes Yes 
Metastatic ability in mice Yes Yes 
 
In the co-culture experiments (chapter 2.3.2) and in the PuMA assay (chapter 2.7) Melmet cells 
transfected with lentiviral vectors expressing GFP-luc were used. GFP is short for green fluorescent 
protein and luc is short for luciferase, an oxidative enzyme catalyzing the oxidation of luciferin to 
oxyluciferin which emits light (figure 2.3). These tags enable us to detect and distinguish Melmet cells 
from other cell types in the PuMA and co-culture assays. The lentiviral vector was a kind gift from Dr. 
Glenn Merlino (Laboratory of Cancer Biology & Genetics, National Cancer Institute, USA)57, and the 
transfection was performed by Lina Prasmickaite (Department of Tumor Biology, Norwegian Radium 
Hospital).    
  
All Melmet cells were cultured with RPMI 1640 medium supplemented with 10 % fetal calf serum 
(FCS) and 1 % GlutaMAX™, hereby referred to as RPMI+. See table 2.2 for an overview over all 
media used in the present study. 
 
2.1.2 WI-38 lung fibroblasts 
The lung fibroblasts WI-38 (#CCL-75) were bought from Americas Type Culture Collection (ATCC). 
The cell line was derived from normal embryonic lung tissue from a Caucasian female. The cells were 
stored in liquid nitrogen. Before use the cells were thawed and transferred to T75-flasks where they 
were cultured in EMEM medium with 10 % FCS. 
 
 
 
 
Table 2.1: Information regarding the Melmet 1 and 5 cell lines. 
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Cell lines Medium Supplements 
Melmet 1 RPMI 1640 10 % fetal calf serum (FCS) 
1 % GlutaMAX™ 
Melmet 5 RPMI 1640 10 % FCS 
1 % GlutaMAX™ 
WI-38 EMEM 10 % FCS 
Melmet 1 or 5 + WI-38 
(co-cultures) 
EMEM 10 % FCS 
 
2.2 General cell work 
2.2.1 Cell culturing and sub-culturing 
Cells were cultured as monolayers in flasks with indicated medium (table 2.2). All cells were grown in 
an antibiotic free environment at 37°C in a 5 % CO2 atmosphere, hereby referred to as “normal 
culturing conditions”. The cell cultures were inspected with an Olympus CKX41SF microscope and 
they were routinely split once or twice a week depending on the cell type. All cell procedures were 
performed under sterile conditions and the cells were tested regularly for mycoplasma infection. 
 
Detachment of cells from cell flasks was done by adding EDTA or trypsin. The cell concentration was 
decided using the Countess™-automated cell counter. Cells were stained with 0,4 % Trypan Blue 
before counting to distinguish between live and dead cells. Only cells with compromised cell 
membranes, dead cells, will absorb Trypan Blue.  
 
2.2.2 APG350 and vemurafenib 
APG350 (Apogenix) was dissolved in PBS from the manufacturer to a stock concentration of 2000 
µg/mL. The aliquots were stored at -80°C. 
 
Vemurafenib/PLX 4032 (Selleck, prod.no. s1267) was dissolved in DMSO to a stock concentration of 
20 mM and aliquots were stored at -20°C. 
 
Table 2.2: Medium types used in the culturing of different cell lines. Supplements to the original medium are also stated. 
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2.3 2D-experiments 
2.3.1 Monocultures 
Melmet cells were diluted in RPMI+ and seeded out in 96-well plates (Nunclon Delta Surface, Thermo 
Scientific). Initially, varying cell numbers were added to each well to determine the optimal cell 
density for the assay. For both cell lines, 7000 cells per well were considered to be the optimal cell 
number. 
 
2.3.2 Co-cultures 
In this experiment we wanted to determine if lung fibroblasts affect the therapy response of 
vemurafenib and APG350 in melanoma cells.  
 
The GFP-luc tagged Melmet cell lines (described in 2.1.1) were co-cultured with WI-38 fibroblast in 
EMEM medium, using 4000 cells of each cell type per well. Melmet cells cultured as mono-cultures in 
EMEM were used as control cells. The cells were seeded out on white, clear-bottomed 96-well plates 
(Corning® Flat clear bottom white microplate) and cultured in standard culturing conditions.  
 
2.3.3 Treatment of 2D-cultures 
The cells were treated with different concentrations of vemurafenib and/or APG350 depending on the 
analysis to follow. See table 2.3 for an overview of the drug concentrations used for the different 
experiments. Each drug concentration was performed in 3-8 parallels and the 96-well plates were 
incubated under normal culturing conditions for 72 hours before analysis. All drug dilutions were 
made in the medium optimized for the cell types used (table 2.2).  
 
2D-experiments Concentration APG350 [µg/mL] Concentration vemurafenib [µM] 
Mono-therapy, dose 
response: 
0,005 – 0,01 – 0,05 – 0,1 – 0,5 – 1 – 
5 – 10 – 20 - 100 
0,033 – 0,66 – 3,3 – 6,6 – 33 – 66 – 
333 - 660 
Combination therapy: 0,01 – 0,1 – 1 0,033 – 0,066 – 0,33 – 3,3 
Conditioned medium: 0,1 0,33 – 3,3 – 6,6  
Co-cultures: 0,1 0,33 – 3,3 – 6,6  
 
 
Table 2.3: Drug concentrations used in 2D-experiments.   
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2.3.3.1 Mono-therapy and combination therapy with vemurafenib and APG350 
Mono-therapy of the cells was done to evaluate the effect of APG350 and vemurafenib alone. The 
results were acquired to evaluate dose response and to select the drug concentrations to be used for 
combination therapy. Twenty four hours after seeding the cells, the medium was removed and 100 µl 
of fresh medium containing either of the drugs or both in combination was added. Since vemurafenib 
is diluted in DMSO, a control consisting of RPMI+ with DMSO was set up alongside the combination 
therapy wells. The amount of DMSO utilized was equivalent to the amount of vemurafenib used for 
each concentration. For an example of a setup used for combination therapy of monocultures see 
figure 2.2.  
 
 
 
2.3.3.2 Conditioned medium infused with vemurafenib and APG350  
To evaluate if normal fibroblasts secrete factors that affect the therapy response of melanoma cancer 
cells, an experiment was set up where Melmet cells were treated with vemurafenib and/or APG350 
infused in fibroblast-conditioned medium. The cells were seeded out and cultured as described in 
chapter 2.3.1 and treated with drugs as described in the previous chapter. The drug dilutions were 
made in EMEM-medium (table 2.2), but the medium was conditioned before use. Cells treated with 
normal, non-conditioned medium were used as control cells.  
 
Conditioned medium was prepared by culturing 500 000 WI-38 fibroblasts in EMEM medium for 72 
hours under normal culturing conditions. The conditioned medium was filtered through a 0,45 µm 
syringe filter to remove dead cells and debris. The medium was used directly after the filtration. 
 
Figure 2.2: Example of a typical setup used for combination therapy of monocultures. The figure models a 96-well plate 
with combinations of APG350 and vemurafenib (PLX) in the first 8 columns and mono-therapy in the last 4 columns.   
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2.3.4 CalcuSyn analysis 
The combined results of four 2D-combination therapy experiments were evaluated for possible 
synergy using the CalcuSyn data program (BioSoft, Feruson, MO, USA). Additionally, two 3D-
experiment parallels were evaluated (chapter 2.4). The program uses the Chou and Talalay 
combination index (CI) to determine the interaction of two drugs (see appendix II for detailed info). 
The inputs were the doses and responses of mono-therapy and combination therapy at different ratios. 
Response-rates were given as dead cells relative to untreated control cells. All negative values, 
indicating increased cell survival, were excluded since the program only accepts positive values. Non-
exclusive CI-values were used. Non-exclusive treatments are defined as treatments affecting different 
targets or different sites of the same target.  
 
2.4 3D-experiments 
Cells cultured as spheroids give a more realistic model of the cell-cell interactions seen in vivo 
compared to 2D-cell cultures34. In this project, 3D-cultures in the format described by Vinci et al33 
were utilized. The results were used to evaluate and support the results from 2D-cultures.  
 
2.4.1 Seeding of spheroids 
To stimulate the formation of spheroids, Melmet 1 and Melmet 5 cells were suspended in RPMI+ and 
200 µL were seeded out in low attachment 96-well plates (Corning® 96 Well Clear Round Bottom 
Ultra Low Attachment Microplate). 3000 cells per well were used based on experiments previously 
performed by Solveig Pettersen. Melmet 1 cells do not form spheroids spontaneously and were 
therefore cultured in RPMI+ mixed with 2 % Matrigel. The spheroids were grown under normal 
culturing conditions for 72 hours before treatment with vemurafenib and/or APG350.  
 
2.4.2 Treatment of spheroids 
To determine the optimal drug concentrations to be used in therapy, spheroids were treated in mono-
therapy with broad ranging concentrations of APG350 and vemurafenib and cultured for 14 days. 
Based on these results concentrations for combination therapy were chosen and set up in 6 parallels 
per drug dose. It was assessed that the spheroids were to be cultured in drug infused medium for 5 
days. Table 2.4 shows the drug concentrations used in this experiment. 
 
 
 
 
Table 2.4: Drug concentrations used in 3D-experiments. 
3D-experiments Concentration APG350 [µg/mL] Concentration vemurafenib [µM] 
Melmet 1: 0,5 – 5 0,33 – 3,3 
Melmet 5: 0,5 – 5 0,066 – 0,33 
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2.4.3 Phase contrast imaging and measurement of spheroid radius 
The spheroids were photographed and measured every day, five days a week. Pictures were taken with 
an Olympus IX81 microscope and the spheroids were measured using the Cell^P computer program. 
The mean cell radius was used to calculate the volume of each spheroid. The volume in mm3 was 
calculated for all spheroid parallels and the average spheroid volume for each therapy dose was 
calculated for each measurement day. These calculations were used to create growth curves depicting 
the spheroids growth from day to day. See appendix III for a calculation example of spheroid volume. 
 
On the 5th day after treatment the spheroids were analyzed with the CellTiter-Glo® Luminescent Cell 
Viability-assay as described in chapter 2.5.2. Before the Glo-reagent was added the spheroids were 
transferred to black, flat-bottomed 96-well plates (Corning® 96 well Black Plate, Clear Bottom with 
lid) along with 50 µL medium. Using opaque-welled plates is important to prevent the luminescent 
signals of each well to leak through to other wells. The medium and spheroids of each well was gently 
pipetted up and down to stimulate spheroid disintegration.  
 
2.5 Cell Viability 
2.5.1 CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS-assay)  
The MTS-assay is a colorimetric assay for measuring the number of metabolically active cells in 
proliferation. MTS, or 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium, is a compound that (together with the electron coupling reagent phenazine ethosulfate 
(PES)) is reduced by dehydrogenase enzymes found in metabolically active cells to form a formazan 
product which is soluble in tissue culture medium. The formazan product gives a copper-brown 
solution and can be quantified by measuring the absorbance at 490 nm. The amount of formazan is 
directly proportional to the number of living cells in culture58. 
 
All monocultured cells used in 2D-experiments were analyzed with the MTS-assay, except 
conditioned medium treated cells. 20 µL of MTS reagent was added to each well, including a column 
of wells containing only cell medium (no cells) used to read background absorbance. The plate was 
incubated under normal culturing conditions for 1 hour. The absorbance at 490 nm was measured with 
a micro plate reader (Wallac Victor2), and the relative viability in % was calculated setting the 
absorbance of untreated control cells as 100 %.  
 
2.5.2 CellTiter-Glo® Luminescent Cell Viability-assay 
The Cell-Titer-Glo® Luminescent assay, hereby called the Glo-assay, is a method used to determine 
the number of viable cells in culture based on quantification of ATP, an indicator of metabolically 
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active cells. The amount of ATP present in the cell culture is directly proportional to the number of 
cells present in culture59. The Glo-assay relies on the generation of a stable luminescent signal 
catalyzed by a thermo-stable luciferase. In the presence of Mg2+, ATP and molecular oxygen, the 
substance beetle luciferin is oxidized to oxyluciferin which gives a stable luminescent signal60. The 
reaction is shown in figure 2.3.  
 
The Glo-assay was performed on all 3D-cultures as well as the experiments where conditioned 
medium was utilized. The 96-well plates were temperate to room temperature for 30 minutes before 50 
µL medium was removed from each well and 50 µL of CellTiter-Glo®-reagent was added (1:1). The 
plates were mixed for approximately 2 minutes on a plate shaker and left for 10-15 minutes in room 
temperature before reading luminescence (1s/well) on the Wallac Victor2-plate reader. 
 
 
 
2.5.3 Luciferase-assay 
By adding D-luciferin to cells expressing luciferase, you get the substance oxyluciferin and light in an 
energy demanding reaction (figure 2.3). Only living cells will express luciferase, therefore the amount 
of light produced is proportional to living cells in culture.  
 
The luciferase-assay was used on the co-culture experiments. 1 µL of luciferin-solution was mixed 
with 199 µL RPMI and added to each well. The wells were previously emptied of the drug infused 
medium. The plate was left for 10 minutes in room temperature before reading luminescence (1s/well) 
on the Wallac Victor2-plate reader. Refer to appendix IV for the protocol on how to make luciferin-
solution. 
 
2.6 Western Immunoblotting 
The Western blot is a method used to detect specific proteins in a sample. Gel-electrophoresis 
separates proteins according to mass and charge, and the proteins are blotted from the gel to a 
membrane using an electrical gradient. Proteins on the membrane can be detected by e.g. antibodies, 
Figure 2.3: The figure illustrates the oxidation of beetle luciferin to oxyluciferin in the presence of a thermo-stable 
luciferase, Mg2+, ATP and O2. Emission of light can be measured as luminescence and is proportional to the amount of ATP 
present. The figure is adapted from the Promega CellTiter-Glo Luminescent Cell Viability Assay protocol60. 
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as is usual in Western immunoblotting. The primary antibody can either be directly conjugated to an 
enzyme, for instance horse radish peroxidase (HRP), or to a secondary antibody conjugated to HRP 
(figure 2.4). Antibody-antigen interactions are specific and therefore allow target proteins to be 
detected in complex protein mixtures. 
 
In this project, membranes were set up with cell lysates from three different biological experiments.  
 
 
 
2.6.1 Culturing, treatment and harvesting of cells for Western Immunoblotting 
Protein lysates were prepared from both Melmet cell lines. Twenty four hours after seeding 4,0*105 
Melmet 1 or Melmet 5 cells in T25 flasks, the cells were treated with APG350 and/or vemurafenib, 
concentrations are presented in table 2.5. The cells were treated for 24 hours before harvesting.  
 
The cells were harvested using a cell scraper, and the cells and the medium were transferred to 15 mL 
tubes, centrifuged at 1000 rpm for 5 minutes and the cell pellets re-suspended in ice cold PBS. The 
cells were transferred to eppendorf tubes, centrifuged at 2000 rpm for 4 min. and the PBS removed. 
The cells were kept on ice during the procedures to stop signaling pathways and inhibit protein 
degradation. The cell pellets were frozen at -80°C. 
 
 
Figure 2.4: Advantages and disadvantages of direct vs. indirect detection methods used in Western blotting. The figure is 
adapted from Thermo Scientific61. 
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Western Immunoblot Concentration APG350 [µg/mL] Concentration Vemurafenib [µM] 
Melmet 1 0,1 0,33 – 0,66 – 3,3 
Melmet 5 0,1 0,33 – 0,66 – 3,3 
 
 
2.6.2 Protein lysates  
The cells were lysed by adding lysis buffer (appendix V) containing protease and phosphatase 
inhibitors following incubation on ice for 1 hour with vortexing every 15 minutes. The samples were 
sonicated for 5 seconds and centrifuged at 13000 rpm for 10 minutes at 4°C to separate cell membrane 
components from the proteins. The supernatant consisting of the protein lysate was transferred to 
eppendorf tubes and frozen at -80°C. 
 
2.6.3 Measurement of protein concentration 
To load an equal amount of protein in each well of the gel, the protein concentration of each sample 
was decided. The protein concentration was measured using the Pierce BCA Protein Assay Kit 
(Thermo Scientific), a colorimetric assay based on the biuret reaction (reducing Cu2+ to Cu1+ in an 
alkaline medium) where Cu1+ is detected using a reagent containing bicinchoninic acid (BCA). The 
reaction product is purple-colored and water soluble and exhibits a strong absorbance at 562 nm. 
According to the producer the absorbance is nearly linear with increasing protein concentrations from 
20 – 2000 µg/mL62. 
 
Standards with concentration from 0 – 2000 µg/mL were prepared according to the producers’ 
protocol, and the samples were diluted in lysis buffer (5µL sample + 55µL lysisbuffer). The samples 
and standards were set up in duplicates. The BCA working reagent was prepared by mixing 50 parts of 
BCA Reagent A with 1 part of BCA Reagent B and 200 µL was added to the samples and standards. 
The samples and standards were incubated at 37°C for 30 minutes and the absorbance was measured at 
540 nm, 1s/well, on the Wallac Victor2 plate reader. The protein concentration was calculated from a 
standard curve based on the absorbance of the standards (0-2000µg/mL). Refer to appendix VI for an 
example of a standard curve with calculations of protein concentration and volume to be applied on 
gels. 
 
2.6.4 NuPAGE® Bis-Tris Electrophoresis System 
The NuPAGE® Bis-Tris Electrophoresis System is an improved version of the well-known SDS-
PAGE system, short for Sodium Dodecyl Sulfate PolyAcrylamide Gel Electrophoresis. SDS is an 
Table 2.5: Drug concentrations used to treat cells for Western Immunoblotting. 
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anionic detergent used to denature proteins and to impart a negative charge to the proteins. This is 
important so that proteins of the same mass move at the same speed through the gel matrix toward the 
anode independent of their former secondary, tertiary and quaternary structure. The polyacrylamide 
gels are made up of a meshwork of fibers forming pores, and the density of the gel will determine the 
proteins speed when wandering through the gel.  
 
In this project we used Life Technologies Novex® NuPAGE® SDS-PAGE gel system. The 
commercial gels are made with Bis-Tris/HCl buffer and SDS is added in the Running Buffer. To 
denature and reduce protein disulphide bonds a loading buffer containing LDS (Lithium Dodecyl 
Sulphate), equivalent to SDS, is added and heated to 70°C. The system provides a neutral pH 
environment during electrophoresis which according to the producer gives a better resolution and 
stability than older systems. 
 
Commercial gels with increasing density of polyacrylamide (4-12 %) were used (Invitrogen). The gels 
were loaded with 10 µg sample; the volume of each sample was calculated from the sample 
concentration and diluted with lysis buffer to a total of 10µL (Appendix VI). Loading buffer was made 
by mixing 2,5 µL LDS Sample Buffer (4x) with 1 µL Sample Reducing Agent (10x), and this was 
added to the samples. The samples were denatured at 75°C for 10 minutes before application on the 
gel. 2,5 µL SeeBlue standard, a molecular weight marker, was added to the first and last well of the 
gel. The electrophoresis was run in 1x MES for 60 minutes at 150 V on an Invitrogen 
PowerEase™500 electrophoresis machine.  
 
2.6.5 Blotting  
All Western blot experiments performed in this project was executed using the dry-blotting system63. 
The transfer of proteins from a gel to a membrane is executed by placing a top and bottom blotting 
stack above and under the gel as shown in figure 2.5. The dry-blotting system differs from the 
traditional wet-blotting by being a more efficient, plug-and-play system with no need for additional 
buffers. 
 
The gels were blotted onto 0,2 µm nitrocellulose membranes using the iBlot™ blotting machine. The 
blot was executed for 8 minutes using a voltage of 23 V.  
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2.6.6 Immunodetection 
The membranes were incubated with selected primary antibodies to detect the protein of interest, and 
these were visualized with secondary antibodies linked to HRP. HRP uses hydrogen peroxide as an 
oxidizing agent to oxidize its substrate. The substrate is found in the development solution 
SuperSignal® West Dura Extended Duration Substrate kit (Thermo Scientific) and 
chemoluminescence is produced by the reaction. Refer to table 2.6 and 2.7 for primary and secondary 
antibodies used in this experiment. 
 
Before the membranes were incubated with a primary antibody they were blocked using a buffer 
consisting of 25mM Tris with pH 7,5 along with 0,15M NaCl and 0,1 % Tween (from here on called 
R&D-buffer, see Appendix VII) which was mixed with milk powder to a 5 % solution. The milk 
solution prevents unspecific binding of the primary antibody and thereby reduces background noise. 
The membranes were incubated in milk solution for 60 minutes and then treated with a primary 
antibody in a 2 % milk or BSA solution over night at 4°C.  
 
The membranes were washed 3x10 minutes in R&D-buffer before they were incubated with secondary 
antibody in a 2 % milk solution for 60 minutes. The membranes were washed 3x10 minutes in R&D-
buffer after the incubation. Washing and incubation was performed with continuous gentle agitation. 
 
The proteins on the membranes were visualized by adding SuperSignal® Solution (Thermo Scientific) 
and quantified using the G_Box (Syngene, England) and the software GeneSnap version 7.12 
(Syngene, England). 
 
Figure 2.5: Blotting stack. The top stack includes 
a copper cathode and a buffer matrix containing 
the necessary ions to create an electrical current. 
The bottom stack contains a copper anode, a 
buffer matrix and a nitrocellulose membrane to 
which the proteins are transferred. The NuPAGE 
gel is situated in the middle. The figure is 
acquired from Life Technologies web page64. 
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Some membranes were stripped of antibodies and re-incubated with a different antibody. The 
membranes were incubated in a stripping solution for 10 minutes with gentle agitation. The stripping 
solution was removed and the membrane rinsed in R&D-buffer before the procedure of blocking and 
incubation with new primary and secondary antibody was repeated. Refer to appendix VIII for details 
about the stripping solution. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
2.7 PuMA-assay 
PuMA, short for pulmonary metastasis assay, is an ex vivo assay developed to show the metastatic 
progression of GFP-expressing cancer cells in the mouse lung environment in real-time65. There has 
been a need for an assay that depicts how metastatic progressions from single cells to metastatic 
lesions at secondary sites occur. Simple in vitro assays do not provide a sufficient model of the 
complex interactions taking place between cancer cells and the tumor microenvironment in regards to 
metastasis. Also, in vivo models for the most part provide end point outcomes of metastasis. The 
Table 2.6: Primary antibodies used for immunodetection on Western blots. 
Primary antibody Dilution Company, cat. # 
Alpha-tubulin (mouse) 1:1000 Sigma, #T9026 
Bad (rabbit) 1:500 Cell Signaling, #9292 
Bid (rabbit) 1:1000 Cell Signaling, #2002S 
Bim (rabbit) 1:1000 Cell Signaling, #2933S 
Casp-3(rabbit)  
pro-casp. + cleaved casp. 
1:1000 Cell Signaling, #9664S, #9662S 
Casp-8 (mouse) 1:500 Alexis, ALX-804-242 
Casp-9 (rabbit) 1:500 Cell Signaling, #9502 
Mcl-1 (rabbit) 1:500 Cell Signaling, #4572S 
PARP (rabbit) 1:500 Cell Signaling, #9542 
pERK 1/2 (rabbit) 1:1000 Cell Signaling, #9102 
pBad Ser112 (rabbit) 1:500 Cell Signaling, #5284S 
pBad Ser136 (rabbit) 1:1000 Cell Signaling, #4366S 
Smac/DIABLO (mouse) 1:1000 Cell Signaling, #2954S 
Table 2.7: Secondary antibodies used for immunodetection on Western blots. 
Secondary antibody Dilution Company, cat. # 
Rabbit anti-mouse 1:3000 Dako, P0260 
Goat anti-rabbit 1:3000 Dako, P0448 
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PuMA-assay is a simple assay that allows one to follow the process of metastatic progression at a 
secondary site over time. Lung tissue provides a 3D collagen network with associated lung epithelial 
cells, inflammatory cells and other stromal elements in which GFP-expressing cancer cells interact65. 
Images can be acquired from day to day and the GFP-expressing cells quantified. 
 
In this study the PuMA-assay was used in the evaluation of therapeutic response at different time 
points after metastatic progression and in an environment with different cells surrounding the cancer 
cells; the tumor microenvironment. Lung tissue from an “athymic nude foxn1 nu” mouse infused with 
Melmet 5 GFP-tagged cells was provided and prepared by Karianne Fleten at the Department of 
Tumor Biology. The Melmet 5 GFP-tagged cells were injected intravenously into the mouse through 
the tail (figure 2.6). The mouse was humanely euthanized with an overdose of Pentoparbital 15 
minutes after cell infusion, and the lung was injected with 1,2 % low melting agarose mixed 1:1 with 
PuMA 2x medium (appendix IX). The lungs were removed from the mouse, cooled in PBS 
supplemented with Penicillin/Streptomycin to a concentration of 100 U/mL and cut by hand into tissue 
section with approximately the same thickness.  
 
 
 
The tissue sections were placed individually onto small squares of Gelfoam® situated in wells of a 24-
well plate. A volume of 300 µL PuMA 1x medium (appendix IX) infused with different doses of 
vemurafenib and/or APG350 was added to the wells (table 2.8). The concentrations of vemurafenib 
were chosen based on the results from 2D- and 3D-experiments as well as previous PuMA-results 
from other members of the group. Untreated control tissue and DMSO treated tissue was included as 
controls. All treatments were set up in two parallels (two tissue sections) and were incubated in 
standard culturing conditions. The medium was changed every Monday, Wednesday and Friday and 
the tissue sections turned on the same days. The lung tissue was cultured for a total of 13 days. 
 
Figure 2.6: Illustration of PuMA assay preperations. 
Melmet 5 GFP-tagged cells are injected intravenously 
through the mouse tail. The lung was injected with an 
agarose/PuMA-medium mix, removed from the mouse 
and tissue sections cut and cultured ex vivo. Image 
adapted from Mendoza et.al.65. 
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PuMA-assay Concentration APG350 [µg/mL] Concentration Vemurafenib [µM] 
Mouse lung tissue infused 
with Melmet 5-GFP cells 
1 – 5 0,066 
 
2.7.1 Phase contrast and fluorescent imaging, quantification of fluorescence intensity 
and immunohistochemistry staining 
Phase contrast and fluorescent images were taken from two different areas of each lung tissue section 
three times a week, resulting in 2 parallel sections x 2 areas of each section = 4 photographs of each 
given treatment.  
 
Quantification of fluorescence intensity was performed using the Java based image processing 
program ImageJ, version 1.43m, developed by Wayne Rasband at the National Institutes of Health, 
USA. The color photographs were transformed to 8-bit grey scale pictures and the threshold was 
adjusted for each picture so that background fluorescence was not included in the calculations. A 
defined area (ROI) was set and quantification limited to this area on all tissue pieces. It was 
endeavored to localize the same area for quantification for every tissue piece from day to day. Particles 
in the ROI were analyzed for the fluorescence intensity, but particles smaller than 50 pixels were 
excluded from the calculations. 
 
Fluorescence intensity was measured as integrated density, a parameter representing colony area 
multiplied with mean pixel intensity. By summing together the integrated density of each colony we 
got a number representing the fluorescence intensity in the given ROI. The average intensity of all four 
photographs of a given treatment was calculated and the results were set relative to the control tissue, 
making the numbers comparable in the graphs. The results give an indication of colony growth from 
day to day. 
 
The tissue sections were fixated in 4 % formalin after 13 days of culturing and sent to 
immunohistochemistry staining at The Norwegian Radium Hospital, Department of Pathology. The 
stained sections were visually inspected and photographed using the Olympus BX51 system 
microscope and Cell^P computer program.  
Table 2.8: Drug concentrations used in treatment of mouse lung tissue for the PuMA-assay. 
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3. Results 
3.1 The sensitivity of Melmet cells to vemurafenib and APG350 
3.1.1 Mono-therapy in 2D-cultures 
The dose response of the mutated BRAF inhibitor vemurafenib and TRAIL receptor agonist APG350 
was evaluated in Melmet 1 and Melmet 5 (Figure 3.1).  
 
 
 
Both cell lines show decreased cell viability with increasing concentrations of vemurafenib, indicating 
that both cell lines are sensitive to the drug (Figure 3.1 A). The graphs show differences in dose 
response; at low concentrations Melmet 1 is less sensitive to the drug than Melmet 5, with a median 
lethal dose (LD50) at approximately 6,6 µM vs. approximately 0,03 µM for Melmet 5 (figure 3.1 C). 
With vemurafenib doses higher than approximately 22 µM the situation is turned and the drug kills 
more Melmet 1 cells than Melmet 5 cells. All Melmet 5 cells were treated with vemurafenib 
concentrations up to 660 µM, but there was no additional effect above 66 µM. 
 
APG350 induces a dose dependent cell killing in both cell lines indicating that they both are sensitive 
to the agent. Melmet 1 has a better response than Melmet 5; a dose of 1 µg/mL killing approximately 
Figure 3.1: The sensitivity of Melmet 1 and Melmet 5 to vemurafenib (A) and APG350 (B). Graph C and D are 
enlargements of the lowest data points in graph A and B respectively. All graphs show viable Melmet cells in % of 
untreated cells. The data points are an average of two and three independent biological experiments and standard error of 
the mean (SEM) is shown.  
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65 % of the Melmet 1 cells vs. 40 % of the Melmet 5 cells (figure 3.1 B). Increasing the dose further 
does not seem to give any additional effect. Rather, it seems that APG350 concentrations above 5 
µg/mL may increase cell survival in the Melmet 1 cell line, as is indicated in the increase of the curve 
in figure 3.1 B. All Melmet 5 cells were treated with APG350 doses up to 100 µg/mL but there was no 
additional effect above 5 µM. Figure 3.1 D shows the lowest data points from figure 3.1 B enlarged.  
 
Vemurafenib is dissolved in DMSO, and the effect of DMSO on cell survival is presented in figure 
3.2. DMSO increases cell survival in both cell lines.  
 
 
 
3.1.2 Combination therapy in 2D-cultures 
Based on the dose response results, concentrations of each drug were chosen for combination therapy 
(Table 2.3 in chapter 2.3.3). The results of the combination therapy with vemurafenib and APG350 are 
shown in figure 3.3.  
 
The Melmet 1 cells response to combination therapy varies depending on the concentration of 
APG350 and vemurafenib utilized (figure 3.3 A). All the tested doses of APG350 combined with low 
vemurafenib doses interestingly give an increase in cell survival compared to APG350 mono-therapy 
(presented as data points x = 0). When increasing the vemurafenib doses to 0,33 µM and higher, 
APG350 0,1 µg/mL (purple graph) reduces cell viability relative to mono-therapy, but all other 
combinations do not induce any additional effect. The results imply that combination therapy on 
Melmet 1 is not effective at most concentrations tested in this study. 
 
Melmet 5 cells respond to combination therapy with increased cell death compared to mono-therapy in 
most of the tested concentrations (figure 3.3 B). All doses of vemurafenib combined with APG350 0,1 
Figure 3.2: DMSO controls of Melmet 1 (A) and Melmet 5 (B) shown as viable cells in % of untreated cells. Four different 
DMSO-concentrations were analyzed, where the amount of DMSO utilized was equivalent to the vemurafenib volume used 
for each given concentration in the combination therapy experiments. The data points are an average of three individual 
biological experiments and SEM is shown.   
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µg/mL and 1 µg/mL induces prominent additional effects of combination therapy. APG350 0,01 
µg/mL (red graph) is the only tested dose that causes cell survival in combination with all the tested 
vemurafenib doses when comparing to vemurafenib mono-therapy. This dose also causes cell survival 
compared to APG350 mono-therapy when combined with the lowest vemurafenib concentration. All 
other combinations give a markedly better effect than mono-therapy. 
 
 
 
CI-values were calculated to evaluate if the different combinations of drugs give a synergistic, 
additative or antagonistic effect (table 3.1). The CI-values for Melmet 1 show that only one 
combination of APG350 with vemurafenib, 0,1µg/mL + 3,3µM, induces synergy, while the rest give 
antagonistic or additative effects. These results are consistent with the combination therapy graphs in 
figure 3.3 A which indicate that combining the two drugs in most cases will not give any additional 
effect compared to mono-therapy. 
Figure 3.3: Melmet 1 (A) and Melmet 5 (B) treated with combinations of vemurafenib and APG350. The graphs show 
viable Melmet cells in % of untreated cells. Vemurafenib is shown on the x-axis and the different colored curves each 
represent a concentration of APG350. The blue graphs show cells treated with vemurafenib as mono-therapy. The red graphs 
show cells treated with vemurafenib combined with APG350 0,01 µg/mL. The purple graphs show vemurafenib combined 
with 0,1 µg/mL APG350 and the green graphs show vemurafenib combined with 1 µg/mL APG350. The data points at x = 0 
show APG350 in mono-therapy. The data points are an average of four independent biological experiments and standard 
error of the mean (SEM) is indicated. Refer to Appendix Xa for combination therapy graphs presented as column charts. 
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For Melmet 5, CI-values for the lowest APG350 concentration (0,01 µg/mL) combined with all 
calculated vemurafenib concentrations give antagonistic or additative results, with CI-values of near 1 
and higher. All the other drug combinations give synergistic effects. The combination giving the best 
combined effect seem to be vemurafenib 0,33 combined with APG350 1 µg/mL. The results of these 
calculations are consistent with what was seen in figure 3.3 B. 
 
 
 
3.1.3 Mono-therapy and combination therapy in 3D-cultures 
Melmet cells cultured as spheroids were treated with vemurafenib, APG350 or a combination of these 
for 96 hours. Spheroid growth, measured as cell volume in mm3 from day to day, is depicted as growth 
curves and microscope pictures in figure 3.4. 
Table 3.1: CI-values calculated for Melmet 1 and Melmet 5 based on the 2D-combination therapy results. Values <1 
indicate synergism, values = 1 imply additative effects and values >1 indicate antagonism. Calculations of CI-values 
were excluded in the cases where combination therapy gave increased survival relative to untreated cells, as described in 
Materials and methods chapter 2.3.4. 
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In Melmet 1 (figure 3.4 A), mono-therapy and combination therapy inhibits spheroid growth compared 
to untreated control spheroids, with combination therapy giving the most reduction in spheroid 
volume. The growth curves show that the untreated control spheroids and the DMSO control spheroids 
(blue lines) increase their volume at approximately the same rate. The mono-therapy APG350 treated 
spheroids (green line) increase their volume during the whole time period, but are significantly smaller 
than the control spheroids. The vemurafenib treated spheroids (red lines) show dose dependent growth, 
with the highest vemurafenib dose giving further reduced volume compared to the lowest vemurafenib 
dose. Combination therapy (orange lines) induces reduction in spheroid volume compared to the other 
therapies and control cells, and additionally inhibits growth to the extent that no gain in volume is seen 
during the period of the experiment. For the highest combination dose the spheroid volume is reduced 
from day 0 to day 4. The experiment included spheroids treated with an APG350 dose of 5 µg/mL 
Figure 3.4: Growth of Melmet 1 (A&C) and Melmet 5 (B&D) spheroids cultured over 96 hours with different 
concentrations of vemurafenib (PLX) and APG350 (APG). The curves (A&B) show spheroid growth on each day as 
spheroid volume in mm3. The data points are an average of two independent biological experiments, where each drug 
concentration/control was set up with 6 parallels. Blue curves indicate control cells, red curves indicate vemurafenib 
treatment, green indicate APG350 treatment and orange indicate combination treatments. Note that Melmet 1 and Melmet 
5 spheroids are treated with different concentrations of vemurafenib. Photographs of Melmet 1 (C) and 5 (D) depict 
spheroid growth on selected days with selected treatment concentrations. See Appendix Xb for growth curves including all 
tested concentrations.  
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(curves not shown, see Appendix Xb), and this treatment did not give any difference in spheroid 
volume compared to APG350 0,5 µg/mL, neither in mono-therapy or in combination with 
vemurafenib. 
 
The Melmet 5 growth curves (figure 3.4 B) show that combination therapy (orange lines) inhibits 
spheroid growth compared to control spheroids (blue lines), but that vemurafenib as mono-therapy 
(red lines) is more effective when comparing to similar doses of combination therapy. The highest 
concentration of vemurafenib mono-therapy is the most effective of the tested drugs and doses in 
regard to reducing spheroid volume. Untreated control spheroids and DMSO control spheroids 
increase their volume at approximately the same rate. Interestingly, spheroids treated with APG350 
seem to grow better than the control spheroids for the first days, with no visible effect of the drug until 
day three and four. As for the Melmet 1 spheroids, the experiment included spheroids treated with 5 
µg/mL of APG350; this treatment dose gave approximately similar spheroid volume as APG350 0,5 
µg/mL, but differed in combination therapy (data not shown, see Appendix Xb). 
 
Figures 3.4 C and D show selected microscope pictures of spheroids from day 0 to day 4. The Melmet 
1 control spheroids increase their size more than Melmet 5 during the period of the experiment. 
Additionally, they are visually less dense and seem more “loose” than the Melmet 5 cells. Both cell 
lines show a reduction in volume compared to control spheroids when treated with drugs. The 
exception may be APG350 mono-therapy in Melmet 5, where a difference is hard to differentiate.   
 
Cell viability of the spheroids on day 4 was evaluated using the Glo-assay (chapter 2.5.2). The results 
are presented in Figure 3.5. In both Melmet 1 and 5 the Glo-results indicate that combination therapy 
gives an additional effect compared to mono-therapy. For Melmet 1 this is consistent with what was 
seen in the growth curves (figure 3.4 A), but differ from the 2D-results (figure 3.3 A). For Melmet 5, 
the Glo-results differ from the growth curves (figure 3.4 B), but are consistent with the 2D-results 
(figure 3.3 B). CI-values calculated from the Glo-data confirm that all tested concentrations give 
synergistic effects (table 3.2). 
 
Comparing figure 3.5 A and B in regard to dose response confirms the findings from 2D-cultures that 
Melmet 1 is more sensitive to APG350 than Melmet 5 is. Interestingly, the results also show that 
Melmet 1 is more sensitive to vemurafenib than Melmet 5, this being opposite of what was seen in the 
2D-cultures. The Glo-results showed, like the growth curves, that a higher APG350 concentration (5 
µg/mL, curves not shown) does not give any increased effect compared with 0,5 µg/mL of APG350 
(Appendix Xc).  
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3.2 Protein expression in Melmet cells treated with vemurafenib and 
APG350  
Western analysis was performed to evaluate the molecular response related to apoptosis in cells treated 
with combination therapy compared to cells treated with mono-therapy or cells without treatment. 
Proteins belonging to the extrinsic apoptotic pathway, activated by e.g. TRAIL-ligand binding, are 
presented in figure 3.6.  
 
Procaspase-8 shows a higher degree of cleavage in combination therapy compared to mono-therapies 
and control samples in Melmet 1, while in Melmet 5 it seems that the protein is most cleaved in 
APG350 treated cells. The cleavage of procaspase-3 is in both cell lines most pronounced in cells 
exposed to combination therapy. Notably, the expression of the 12 kDa active caspase-3 band is 
stronger in both cell lines (figure 3.6 A and B). Also PARP, which is cleaved by caspase-3, has a higher 
degree of cleavage after the combination therapy. 
Figure 3.5: Melmet 1 spheroids (A) and Melmet 5 spheroids (B) analyzed with the Glo-assay after 96 hours of culturing in 
drug-infused medium. APG350 (APG) concentrations are given in µg/mL, vemurafenib (PLX) concentrations are given in 
µM. Note that Melmet 1 and Melmet 5 cells are treated with different vemurafenib concentrations. A DMSO control was 
included where the amount of DMSO utilized was equivalent to the vemurafenib volume used for the highest analyzed 
vemurafenib concentration. Each column represents the average of two individual biological experiments showing the cell 
viability in % of untreated cells. Standard error of the mean (SEM) is indicated. Selected treatment concentrations are shown; 
see Appendix Xc for all concentrations used in the experiment. 
  
Table 3.2: CI-values calculated from the Glo-data of Melmet 1 and Melmet 5 spheroids. All values indicate synergism (< 1). 
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Protein members of the intrinsic apoptotic pathway are shown in figure 3.7. Investigation of the 
expression of these proteins gives an indication of how the different drug treatments affect this 
pathway. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Western blots showing protein expression in Melmet 1 (A) and Melmet 5 (B). The blots presented are 
representative for three different biological experiments. DMSO controls were not included for the Melmet 5 cells in the 
shown parallel, but were included in the other parallels. The APG350 concentration = 0,1 µg/mL. The vemurafenib 
concentration = 0,33 µM.  
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Cleavage of Bid links the extrinsic and intrinsic pathway. In Melmet 1 (figure 3.7 A), Bid is cleaved in 
all therapies, but to a higher degree in samples treated with vemurafenib mono-therapy and 
combination therapy than in APG350 mono-therapy treated samples. In Melmet 5 (figure 3.7 B) the 
control sample displays cleaved Bid and there does not seem to be any substantial difference between 
control sample and the therapy treated samples. Smac/DIABLO, which is a pro-apoptotic protein, does 
not show any significant difference between control samples and therapy treated samples in Melmet 5, 
while BimEL is slightly increased in the combination therapy sample compared to the control sample. 
In Melmet 1, Smac/DIABLO is down-regulated only in APG350 treated samples. Bim is upregulated 
in samples treated with vemurafenib mono-therapy and combination therapy and APG350 mono-
therapy samples are reduced. The pro-apoptotic protein Bad, on the other hand, is in both cell lines 
reduced in vemurafenib mono-therapy samples and combination therapy samples compared to control 
cells.  
Figure 3.7: Western blots showing protein expression of intrinsic family members in Melmet 1 (A) and Melmet 5 (B). The 
blots presented are representative for three different biological experiments, except for Bid and Smac/DIABLO which 
were only performed once. DMSO controls were not included for the Melmet 5 cells in the shown parallel, but were 
included in the other parallels. The APG350 concentration = 0,1 µg/mL and vemurafenib concentrations = 0,33 µM.  
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Phosphorylation of Bad inactivates the proteins pro-apoptotic abilities. In this study antibodies 
detecting pBad phosphorylated at serine 112 and 136 were investigated, both showing similar 
expression patterns (serine 112 is shown in figure 3.7). In Melmet 1, pBad expression is increased in 
both vemurafenib mono-therapy treated samples and combination therapy samples compared to the 
untreated control sample. Mcl-1, on the other hand, is reduced in the same samples. For APG350 
treated samples, both proteins are reduced compared to the control samples. It should be noted that the 
DMSO control of the pBad-blot is increased compared to the untreated control. In Melmet 5, pBad is 
reduced in vemurafenib mono-therapy treated samples compared to the other samples. Mcl-1 is 
increased in the same sample when comparing to the other therapy treated samples, but similarly 
expressed as the control sample. Samples treated with APG350 mono-therapy and combination 
therapy are reduced in Mcl-1 compared to the control sample. 
 
Caspase-9 is a caspase cleaved in the apoptosome and which can activate caspase-3. In Melmet 1, 
combination therapy induces more abundant cleavage of caspase-9 compared to control cells and 
mono-therapy treated samples. Caspase-9 in the APG350 treated samples is also cleaved, but less than 
in the samples treated with combination therapy. In Melmet 5, the same trends can be observed, but 
the differences are not as clear. 
 
The protein pERK was analyzed to investigate the effect of vemurafenib on the cell lines. No effect on 
pERK was observed in any of the two cell lines after 24 hours (figure 3.8). 
 
 
 
3.3 Evaluation of lung fibroblasts impact on Melmet cells exposed to 
vemurafenib and APG350  
Stromal cells have been shown to have an impact on drug response32. To determine the impact lung 
fibroblasts have on vemurafenib- and APG350 therapy, either by secreted factors or by direct cell-cell 
Figure 3.8: Western blots of the protein pERK in Melmet 1 (A) and Melmet 5 (B). The blot was executed from one 
biological experiment.  
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interactions, Melmet cells were cultured in conditioned medium from WI-38 lung fibroblasts or co-
cultured with the WI-38 cells.  
 
 
 
A difference in drug response is seen in both Melmet 1 and Melmet 5 when cells are cultured in 
conditioned medium (dark colored columns) vs. cells cultured with normal medium (light colored 
columns) (Figure 3.9 A and B). The effect of vemurafenib mono-therapy (red bars) is notably 
decreased in conditioned medium grown cells, indicating a rescue effect induced by factors in the 
conditioned medium. In APG350-treated cells (green bars), the conditioned medium interestingly 
inflicts an opposite effect; an increased dose response to the drug. For combination therapy the results 
differ between the cell lines. Melmet 1 does not get an obvious rescue effect from the conditioned 
medium, while Melmet 5 cells do. This is interesting as both cell lines show a similar response in 
mono-therapy. 
 
In the co-culture experiments (figure 3.9 C and D), the fibroblast effects observed in Melmet 1 differ 
from the effects seen in Melmet 5 in all therapies. Melmet 1 is saved from vemurafenib mono-therapy 
Figure 3.9: Melmet 1 (A&C) and Melmet 5 (B&D) cultured in conditioned medium from WI-38 fibroblasts (A&B) or as co-
cultures with WI-38 fibroblast (C&D). Cells cultured in conditioned medium or as co-cultures are visualized as dark colored 
columns. Light colored columns are cells grown in normal, unconditioned medium or as mono-cultures consisting of Melmet 
cells. Concentrations of APG350 (APG) and/or vemurafenib (PLX) are indicated on the x-axis. Each column represents the 
average of three individual biological experiments showing the cell viability in % of untreated cells. Standard error of the 
mean (SEM) is indicated. 7000 cells/well were cultured for the conditioned medium experiments, 4000 cells per well were 
utilized in the co-culture experiments. 
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but not from combination therapy, and an increased dose response is seen in cells treated with APG350 
mono-therapy. Melmet 5 cells, on the other hand, are rescued from combination therapy and APG350 
mono-therapy, but not from vemurafenib mono-therapy. Comparing these results to the conditioned 
medium experiments (figure 3.9 A and 3.9 B) show consistency in the Melmet 1 cell line but 
differences in Melmet 5, though combination therapy shows the same rescue effect in both experiment 
types. It should be noted that the highest combination therapy doses of the microenvironment 
experiments seem to induce synergistic effects in Melmet 1 cells, unlike the initial 2D-culture 
experiments (figure 3.3 A). 
 
3.4 Evaluation of mono-therapy and combination therapy in mouse lung 
tissue  
The PuMA assay demonstrates the therapeutic response of vemurafenib and APG350 in Melmet 5 
cells growing in a lung microenvironment with various stromal cells and ECM components. The 
photographs of the lung tissue sections (figure 3.10) indicate reduced growth of cancer cells in the 
tissue sections exposed to either mono-therapy or combination therapy compared to untreated control 
samples. In the control sections, the number of Melmet 5 colonies decreases in number but increases 
in size and intensity during the time period of the study. Mono-therapy of vemurafenib and APG350 
inhibits colony growth both in size and number compared to the control cells, the effect of APG350 
mono-therapy seemingly better than the effect of vemurafenib mono-therapy at the selected doses. 
Response to combination therapy seems better than the mono-therapies, even though the difference is 
less clear when comparing with APG350 mono-therapy. Substantial variation in regard to background 
fluorescence was observed for the different tissue sections.  
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Quantification of intensity as integrated pixel density (mean grey value*area) was performed to get a 
more objective evaluation of the PuMA photographs. The results show that the Melmet 5 colonies 
have a relatively better response to combination therapy than to mono-therapy in the shown doses 
(figure 3.11), but that the standard deviations are very high, making the results unreliable. Note that 
APG350 as mono-therapy for the most part shows a higher intensity than vemurafenib as mono-
therapy, something that differs from the photographs presented in figure 3.10.  
 
 
Figure 3.10: Fluorescent photographs of mouse lung tissue sections with Melmet 5 GFP-tagged cells. Selected treatment 
days and selected concentrations of APG350 (APG) and vemurafenib (PLX) are shown. Background fluorescence has been 
subtracted in the photographs to better visualize the colonies.  
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Tissue sections were sent to immunohistochemistry staining after 13 days of culturing. The expression 
of GFP and KI-67 was monitored and are shown in figure 3.12. A clear difference in GFP- and KI-67-
expression is observed when comparing the control tissue to the drug treated tissue, though APG350 
mono-therapy and combination therapy are similar. 
 
In addition to the concentrations presented in figure 3.10, 3.11 and 3.12, an APG350 dose of 1 µg/mL 
was included in the experiments. There was both a visual and a quantifiable reduction between 1 
µg/mL and 5 µg/mL. See appendix Xd for the integrated density graphs containing all tested 
concentrations.  
 
Figure 3.11: Average integrated density quantified from pictures of the PuMA tissue sections. The columns are presented 
relative to day 0. Two different areas of two parallel tissue sections (total of four areas) were analyzed by measuring integrated 
density using the ImageJ computer program. This value reflects the fluorescence intensity in the selected ROI. Standard 
deviation is shown. APG350 (APG) and vemurafenib (PLX) as mono-therapy are highlighted in green and red, respectively. 
Combination therapy is highlighted in orange. 
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Figure 3.12: Expression of GFP and KI-67 in IHC stained tissue sections treated with APG350 (APG) and/or vemurafenib 
(PLX) vs. control medium for 13 days.  
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4. Discussion 
In the present work, combination therapy with vemurafenib and APG350 has been evaluated in the cell 
lines Melmet 1 and Melmet 5, both with and without influence of microenvironmental factors. The cell 
lines are responsive to both drugs, and combination therapy leads to both synergistic and antagonistic 
effects depending on the cell line, culture type and drug dose utilized. Additionally, microenvironment 
factors affect the cancer cells response to therapy. 
 
In Melmet 5, which is a proliferative, low invasive cell line, the 2D-culture experiments show that 
combinations of vemurafenib with APG350 doses above 0,01 µg/mL induces synergistic effects 
compared to mono-therapy. This trend was confirmed in spheroids analyzed with the Glo-assay and in 
cells grown in lung tissue (results presented in chapter 3.1.3 and chapter 3.4). The Melmet 5 spheroid 
growth curves (figure 3.4 B), based on measurement of cell volume from day to day, did not indicate 
synergism. This may be explained by inaccuracy in the measurement of the spheroids. The Melmet 5 
spheroids were more difficult to measure than Melmet 1 due to their edges being less defined when 
treated with combination therapy compared to untreated spheroids. Additionally, the density of the 
spheroids seemed to be reduced in response to therapy, making the perimeter blurred and the spheroids 
bigger.  
 
Western analysis of the cell line shows that the extrinsic apoptosis pathway is activated to a higher 
degree in cells treated with combination therapy than mono-therapy, with more cleavage of caspase-3 
and PARP. Active caspase-3 cleaves vital proteins in the cell, and the cleavage of PARP indicates that 
caspase-3 is functional. Protein members of the intrinsic apoptosis pathway were more ambiguously 
expressed, with the pro-apoptotic proteins Bad and Smac/DIABLO being both down-regulated and 
similarly expressed in combination therapy samples vs. control samples, and the anti-apoptotic protein 
pBad showing slight down-regulation. Bim is known to be a potent apoptosis inducer43 and BimEL is 
slightly upregulated in the cell line. This, along with the downregulation of the anti-apoptotic protein 
Mcl-1 indicates that apoptosis through the intrinsic pathway is activated. Additionally, cleaved 
caspase-9 is to some extent increased in combination therapy treated samples. It is the balance 
between the pro- and anti-apoptotic proteins that determines to which degree apoptosis is initiated, and 
the limited range of proteins tested in this project is not sufficient to evaluate the pathways full 
activation status. If both the intrinsic and extrinsic apoptosis pathways are active, the cells will have a 
stronger apoptotic response than the extrinsic pathway alone. Overall, the results give a strong 
indication that the Melmet 5 cell line responds better to combination therapy compared to vemurafenib 
mono-therapy, the standard treatment offered to V600E mutated BRAF patients to date. 
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Melmet 1, which is an invasive, low proliferative cell line, shows varying response to combination 
therapy depending on the culturing method and drug dose utilized. In 3D-cultures, the spheroids 
clearly show an additional effect of combination therapy compared to mono-therapy when considering 
both the growth curves (figure 3.4 A) and Glo-results (figure 3.5 A). In the 2D-cultures, on the other 
hand, combination therapy does not give synergistic effects in the cells. Quite the contrary, many of 
the tested drug doses lead to an increase in cell survival, indicating that combination of the two drugs 
may induce cancer-favorable responses in the cells. Interestingly, Western analysis of Melmet 1 cells 
cultured in 2D indicate higher apoptosis activation in combination therapy vs. mono-therapy treated 
cells, as seen in the levels of cleaved caspase-8, cleaved caspase-3 and cleaved PARP (figure 3.6). 
Additionally, the cleavage of Bid and caspase-9 indicates that also the intrinsic apoptosis pathway is 
active, and the upregulation of all Bim variants and downregulation of Mcl-1 support this claim. All 
data indicates activation of apoptosis and increased cell death in combination therapy contrary to the 
2D-cell viability results. This suggests that resistance mechanisms downstream of the proteins 
investigated in this study may be active, or that caspase-3 is partly inhibited e.g. by XIAP. It should be 
noted that cells for Western analysis were harvested 24 hours after treatment while cell viability assays 
were performed 72 hours after treatment and the results are therefore not directly comparable. Some 
proteins are likely to be differently expressed at the two time points and cells for Western analysis 
should therefore have been harvested at several different time points.  
 
There exists convincing evidence that 3D-cultures are better mimics of living tissue and more 
accurately reflects complex in vivo environments compared to cells grown as 2D-monolayers31, 34, 66, 67. 
Therapy response in cells may thus differ depending on the culture type utilized68, 69. Based on these 
studies and the promising 3D results for Melmet 1, it is possible that Melmet 1 will be sensitive to 
combination therapy in vivo. 
 
It should be noted that Melmet 1 does not form spheroids spontaneously as Melmet 5 does. They are 
dependent on Matrigel for spheroid-formation, and it was not determined if the Matrigel affects the 
cells’ therapy response. However, the microscope photographs of the spheroids (figure 3.4 C and D) 
show that Melmet 1 differs from Melmet 5 in appearance, seeming looser and less dense. One can 
speculate if the anatomy of the Melmet 1 spheroids may help the drugs penetrate into the spheroid and 
in that way better distribute its effect, leading to increased therapy response. If this is the case it may 
explain why Melmet 1 is more sensitive to vemurafenib than Melmet 5 in 3D-cultures, when opposite 
results are observed in the 2D-cultures.  
 
As mentioned in Results chapter 3.3, Melmet 1 cells show a beneficial effect of combination therapy 
in the microenvironment experiments, unlike what was observed in the initial 2D-culture experiments. 
Some of the experimental factors differ between the experiments, which may explain the observed 
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variation. Firstly, the MTS-, Glo- and luciferase-assays were utilized interchangeably, but when 
compared it was shown that similar results were obtained regardless of assay used (data not shown). 
The number of Melmet cells was reduced in co-cultures to make room for fibroblast cells, and a low 
cell number increased the effect of vemurafenib and APG350, as seen when comparing drug response 
in co-cultures (figure 3.9 C and D) to response in conditioned medium experiments (figure 3.9 A and 
B). This was also evaluated in a separate experiment where 4000 vs. 7000 Melmet cells per well was 
compared (data not shown). One can speculate if the increased cell death occurs because the drugs 
have a better effect on fewer cells or if they are less content when they have fewer neighbors of similar 
cell type and therefore die more easily. In addition to this, the vemurafenib concentration was 
increased in TME-experiments to evaluate if higher vemurafenib doses would give increased effect of 
combination therapy in Melmet 1. The two highest doses do induce an additional effect in combination 
therapy treated cells vs. mono-therapy treated cells, but the results also show that all the tested doses 
of vemurafenib mono-therapy are more potent than what was observed in the initial 2D-combination 
therapy experiments. Whether this increased vemurafenib effect is due to differences between the 
utilized vemurafenib batches or something else is not known. In any case, these results indicate that 
increased vemurafenib doses may counteract antagonistic effects observed from the initial 2D-
combination therapy.   
 
Explanations of the antagonism seen in 2D-cultures of Melmet 1 when combining the two drugs can 
be related to studies of pro-survival mechanisms induced by TRAIL. TRAIL has been related to ERK 
activation49, 70, 71, NF-κB activation48, as well as activation of the PI3K-AKT-pathway70. Studies show 
that TRAIL-induced ERK activation is associated with suppression of apoptosis70 and Zhang et. al. 
(2003)71 has provided evidence that TRAIL-mediated ERK activation protects melanoma cell lines 
from apoptosis by inhibiting Smac/DIABLO release from the mitochondria. In this study the 
Smac/DIABLO expression (figure 3.7) was decreased after 24 hours only in APG350 treated samples 
and not in combination therapy, and pERK expression remained unchanged after exposure to all 
therapies (figure 3.8). However, the localization of Smac/DIABLO was not studied and may still be 
mitochondrial. The lack of pERK inhibition after vemurafenib treatment was unexpected since both 
cell lines show response to vemurafenib in cell viability assays. This could be related to the harvesting 
time point or the vemurafenib concentration utilized. It should also be noted that the results of pERK, 
Smac/DIABLO and Bid expression were only studied in cells from one biological experiment.  
 
Another TRAIL-induced survival mechanism is related to the activation of AKT, which can lead to 
phosphorylation of Bad at serine 13672. Bad is a pro-apoptotic protein which when phosphorylated will 
be sequestered and left inactive, thereby suppressing cell death. The expression of pBad is however 
not increased after APG350-treatment in this study, indicating that AKT in this case is not activated by 
TRAIL. AKT can also activate IKK, a subunit of NF-κB, leading to activation of the NF-κB 
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transcription factor. Protein products downstream of NF-κB have not been investigated here, but 
TRAIL-resistant cells have been shown to activate NF-κB leading to increased proliferation48. The 
cells of this study are not fully resistant as they show a dose dependent response to low APG350 
concentrations, but because higher doses do not give additional effects it may imply that innate 
resistance is an issue.  
 
Resistance to vemurafenib after initial response is well-documented, and several resistance 
mechanisms are identified23, 24. High levels of activated NRAS and increased levels of C-Raf are often 
found in cell lines with acquired vemurafenib resistance and may lead to reactivation of the MAPK-
pathway. Indirect activation of PI3K-AKT is also a proposed resistance mechanism. Combination 
therapy is a much used strategy to overcome resistance. When combining vemurafenib with APG350 
one not only targets the MAPK-pathway but also activates apoptotic pathways. In theory, targeting 
several cellular pathways simultaneously could shift the cells balance toward death, hopefully 
overcoming resistance issues. But it is also possible that the combination provides over-stimulation of 
other survival pathways, like PI3K-AKT which in theory is activated by both vemurafenib and 
APG350. To summarize, the two drugs have the potential to activate different cellular pathways which 
can interact with each other to shift the cells balance in favor of survival or death. It can be 
hypothesized that combination therapy in some cases may shift the cells balance toward survival, 
explaining the antagonism seen in 2D-cultures of Melmet 1. Even when combination therapy induces 
synergy, these alternative pathways may contribute to reduce the effect of combination therapy on the 
cells. Additional studies are needed to identify mechanisms involved when combining the two drugs.  
 
Vemurafenib is dissolved in DMSO, and in our hands DMSO alone increased the cell viability of both 
cell lines by up to 30 % in 2D-cultures (figure 3.2) and up to 10 % in spheroids (figure 3.5). The 
increase in cell viability has been observed by other representatives in Gunhild Mælandsmo’s group, 
but is not directly documented in the literature. However, DMSO’s ability to induce cell differentiation 
and cell-surface alterations has previously been shown73-75, and Bentel et. al. (1990)76 reported that 
epithelial cell lines cultured in the presence of DMSO could lead to enhanced invasiveness. 
Additionally, DMSOs protective effects in different models have been previously reported, as 
reviewed by Kelava et.al. in 201177. These data suggests that DMSO possesses properties that can 
affect the cells, and thereby DMSO present in the vemurafenib solution may influence drug response, 
making the dose response curves skewed. By relating the dose responses to DMSO control cells 
instead of untreated control cells the data may be more representable. Graphs showing this are 
included in the appendix Xe. Oddly, DMSO does not seem to increase cell survival in vemurafenib 
mono-therapy treated cells, as seen by the lack of increase in the blue graph in figure 3.3 A. Why this 
is the case is not known, but it may seem that DMSO alone and in combination with the two tested 
drugs has an adverse effect on cells which is not triggered by vemurafenib alone. 
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The effect of the tumor microenvironment (TME) on tumor response to therapy has been previously 
documented in several articles32, 68, 78-80, where Straussman et al. (2012)32 show that several fibroblast 
cell lines, WI-38 included, can induce melanoma cell resistance to RAF-inhibitors. In the present 
study, WI-38 lung fibroblasts decrease the effect of vemurafenib and increase the effect of APG350. In 
Melmet 1 the fibroblasts do not seem to affect combination therapy, while a rescue effect is seen in 
combination therapy of Melmet 5. The conditioned medium experiments indicate that it is fibroblast 
secreted factors which contribute to rescue the Melmets from therapy. For instance Hepatocyte growth 
factor (HGF) secreted by fibroblast cells can reactivate the MAPK pathway, PI3K-AKT-pathway and 
the HGF receptor MET in melanoma cells, thereby contributing to RAF-inhibitor resistance32. Cell-
cell contact, as simulated by the co-culture experiments, was comparable to conditioned medium 
results in Melmet 1. In Melmet 5, however, cell-cell contact may counteract the protecting effects of 
fibroblast-secreted factors on mono-therapy treated cells, while combination therapy remained 
unchanged. It must be emphasized that different cell-types present in the TME may affect tumor cells 
in several ways, and that the TME experiments of this study only indicate the effect of WI-38 
fibroblasts. In the PuMA-assay, on the other hand, a wider variety of TME-factors are present and the 
results of the assay reveal that the tested drugs induce toxic effects on Melmet 5 growing in a lung 
environment. It can therefore be assumed that factors of the TME in this case are not able to save the 
cancer cells from therapy. However, it is not known whether the drugs’ effects are reduced due to 
TME-interactions. 
 
It should be noted that the PuMA-assay, developed by Mendoza et al.65, is a new and not fully 
established assay at the Department of Tumor Biology. Experiences and knowledge acquired during 
this project have contributed to a more optimized protocol, but the data presented in this thesis is not 
standardized to the extent that is required for publications and the assay was only performed once. The 
standard error calculated for the average integrated density data are very high (figure 3.11), reflecting 
a large variation between the tissue sections and areas analyzed. This variation is probably due to two 
major factors. Firstly, the ROI being analyzed in each photograph was placed manually and the tissue 
morphology to some extent changed each time the sections were turned, making the exact same 
placement of the ROI difficult. Secondly, and probably even more critical, is the fact that the number 
of colonies in each tissue section on day 0 showed substantial variation, as well as different growth 
patterns during the extent of the experiment. Colony growth in some cases seemed to be directed 
“downwards” below the tissue surface, while in other cases the growth was lateral in the surface area. 
This will give variations in regard to the fluorescence intensity detected that does not relate to the 
actual colony growth or size. By utilizing a tissue slicing machine which can provide more evenly and 
thinner slices of tissue than manual slicing, it might be possible to diminish this variation to a more 
acceptable level. Additionally it has been proposed that by using the IncuCyte™ live content imaging 
system (Essen BioScience), the exact same part of each tissue section will be photographed each day. 
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Additionally, the IncuCyte™ may solve issues in regard to varying picture quality and background 
fluorescence. 
In summary, the present project has shown that combination therapy with APG350 and vemurafenib is 
capable of reducing growth of Melmet cells in several culture types and that the tumor 
microenvironment does affect the therapy efficacy. Differences between the cell lines were shown, 
with Melmet 5 giving more consistent results than Melmet 1. These variations may reflect upon the 
cell lines differences in phenotype, stressing the importance of a thorough examination and profiling 
of patient material before initiation of therapy. Importantly, results of the present project emphasize 
that TME-interactions need to be taken into account when designing new therapy regiments. 
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Future perspectives 
The relative short time period of this project causes several questions to be left unanswered, and 
further investigations are necessary before any conclusions about the effect of vemurafenib and 
APG350 in combination can be drawn.  
 
First of all, to confirm the results of the present project, more melanoma cell lines need to be tested to 
validate the generality of the drug combinations. Additionally, different factors of the experiments 
need to be more strictly controlled; therefore additional studies on the influence of Matrigel on therapy 
response should be initiated, along with further studies of how to reduce DMSO’s effect on melanoma 
cells. Cell lines which are resistant to vemurafenib and cells resistant to TRAIL-treatment ought to be 
tested to evaluate if combination therapy can help overcome resistance. The effect of combination 
therapy on stromal cells should also be tested. 
 
Resistance mechanisms activated by combination therapy, potentially leading to increased cell 
survival, need to be explored to a greater extent. Proteins part of the NFκB and PI3K-AKT signal 
pathways, as well as proteins related to caspase-3 inhibition, like IAPs and cFLIP, should be 
investigated. Additional studies of Smac/DIABLO and ERK-activation is also necessary.   
 
The PuMA-assay needs further optimization by implementing the proposed changes of utilizing a 
slicing machine for preparation of lung sections and using the IncuCyte™ for live imaging. If these 
alterations prove successful the assay should be utilized on several melanoma cell lines. This can give 
interesting information regarding melanoma cells response to combination therapy in an environment 
to which they tend to metastasize. An important step would also be to test the effect of combination 
therapy in vivo in mouse-models. 
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Appendix 
I) List of reagents and materials 
Reagents and materials: Company: Cat. #: 
1 M Tris   
5 M NaCl   
10 M NaOH   
12 M HCl   
20 % Tween   
APG350 Apogenix  
BX51 system microscope Olympus  
BX-UCB, external system controller Olympus  
Cell scraper 30 cm TPP® 99003 
CellTiter 96® Aqueous One Solution Reagent Promega G3580 
G3581  
CellTiter-Glo® Reagent Promega G7571 
CKX41 inverted microscope Olympus  
Corning® 96 Well Flat Clear Bottom White 
Polystyrene TC-Treated Microplate 
Corning Incorporated 3610 
Corning® 96 Well Flat Clear Bottom Black Plate, 
TC-treated  
Corning Incorporated 3603 
 
Corning® 96 Well Clear Round Bottom Ultra Low 
Attachment Microplate 
Corning Incorporated 7007 
Countess™-automated cell counter Invitrogen™ C10227 
Countess™-cell counting chamber slides Invitrogen™ C10283 
D-Luciferin 1g BioThema BT11-1000 
Dimethyl Sulphoxide (DMSO) Hybri-max™ Sigma-Aldrich D2650 
EDTA Versene® 0,02 % Lonza, BioWhittaker® BE17-711E 
Eagle's Minimum Essential Medium (EMEM) ATCC 30-2003 
Finnpipette® Stepper pipette Thermo Scientific 4540 
Finntip® Stepper tips Thermo Scientific 9404 
Fetal calf serum (FCS) PAA A15-101 
Formalin, 4 % Merck  
Gelfoam® 12-7mm absorbable, 12cm2 Pfizer 272575 
GlutaMAX™ (100x) Gibco® by Life technologies 35050-038 
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Glycine Merck  
Huvec super, MVDB 131 medium (1x) Gibco® by Life technologies 10372-019 
iBlot Gel Transfer Stacks Nitrogencellulose, 
regular 
Invitrogen™ IB3010-01 
iBlot™ blotting machine Invitrogen™  
IX81® Motorized Inverted Microscope Olympus  
IX2-UCB external system controller Olympus  
Matrigel™ Basement Membrane Matrix BD Biosciences 354234 
NuPAGE® Novex 4-12 % Bis-Tris Midi Gel Invitrogen™ WG1401BOX 
NuPAGE® LDS sample buffer (4x) Invitrogen™ NP0008 
NuPAGE® MES SDS Running Buffer (20x) Invitrogen™ NP000202 
NuPAGE® Sample reducing agent (10x) Invitrogen™ NP0009 
Nunc™ EasYflasks, nunclon delta treated with 
blue filter cap. 
Thermo Scientific 156499 
156367 
Nunclon Delta Surface, 96-well plate Thermo Scientific 167008 
Nunclon Delta Surface, 24-well plate Thermo Scientific 142475 
PBS BioWhittaker® BE17-516F 
PowerEase™500 Invitrogen™  
M199 medium (1x) Gibco® by Life technologies 31150-022 
Phosphatase inhibitor cocktail tablets, PhosSTOP  Roche  04 906 837 001 
Pierce® Bovine Serum Albumin Standards Thermo Scientific 23209 
Pierce® BCA Protein Assay Kit Thermo Scientific 23227 
Pierce® BCA Protein Assay Reagent A Thermo Scientific 23228 
Pierce® BCA Protein Assay Reagent B Thermo Scientific 23224 
Protease inhibitor cocktail tablets, cOmplete Mini Roche 04 693 124 001 
RPMI 1640 cell medium BioWhittaker® BE12-167F 
SeeBlue® Plus2 Prestained Standard (1x) Invitrogen™ LC5925 
SuperSignal® West Dura Extended Duration 
Substrate 
Thermo Scientific # 34076 
 
SuperSignal® West Dura Stable Peroxide Buffer Thermo Scientific #1859025 
SuperSignal® West Dura Luminol/Enhancer 
Solution 
Thermo Scientific # 1859024 
 
Syringe, 10 mL BD Plastipak™ 302188 
Syringe filter, 0,45 µm cellulose acetate VWR 28145-481 
Trypan Blue stain 0,4 % Gibco® by Life techonolgies 15250-061 
UltraPureTM 1M Tris-HCl, pH 7.5 Invitrogen™ 15567-027 
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Vemurafenib/PLX 4032 Selleck Chemicals LLC S1267 
Batch: 
S126703 
S126705 
S126709 
Wallac Victor2 1420 Multilabel counter Wallac  
X-Cite® 120 PC Q, fluorescence light source  Lumen Dynamics  
 
II) Details related to the Calcusyn data program 
The CI value of non-exclusive treatments is calculated by the formula: 
CI = (Da + Db)/(Dxa + Dxb) + Da*Db/Dxa*Dxb. 
Da and Db are doses needed of treatment A and B to inhibit x % of cell proliferation as single 
treatments, and Dxa and Dxb are the doses of A and B to inhibit x % of cell growth in a combination 
regimen. 
 
III) Example of spheroid volume calculations  
The volume inside a sphere is derived to be 𝑉 =
4
3
𝜋𝑟3 where r is the radius of the sphere. If Cell^P 
measured the mean radius of the spheroid to be 418,14 µm the volume will be 306231894,5 µm3 
equivalent to 0,306 mm3.  
 
IV) Luciferin solution 
1. D-Luciferin 1 g (BioThema) was dissolved in 35 mL PBS to make a white solution with 
approximately pH 5. 
2. Use 10M NaOH to adjust the pH to 7,5 – 7,8. 
3. If pH is too high, adjust with HCl 
4. Fill to 50 mL with PBS. 
5. Store at -20°C. 
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V) Lysis buffer 
For 50 mL lysis buffer: 
 
20 mM Tris-HCl pH 7,5 = 1 mL 1M Tris-HCL pH 7,5 
137 mM NaCl   = 1,37 mL 5 M NaCl 
100 mM NaF   = 5 mL 1 M Na F 
10 % Glycerol   = 5 mL Glycerol 
1 % NP-40   = 5 mL 10 % NP-40 
    Fill with dH2O to 50 mL 
 
Add 1 protease inhibitor cocktail tablet, cOmplete Mini (Roche) to 500 µL dH2O. 
Add 1 phosphatase inhibitor cocktail tablet, PhosSTOP (Roche) to 500 µL dH2O. 
50 µL phosphatase stop and 50 µL protease stop is added to 1 mL lysis buffer. 
 
VI) Example of protein concentration and protein volume calculations   
The Pierce BCA Protein Assay Kit (Thermo Scientific) was utilized to measure the absorbance of each 
sample in two parallels. The average of the parallels was calculated and the background absorbance 
subtracted. The protein concentration was calculated utilizing the standard curve equation (see 
example below), where x = concentration and y = absorbance. Note that the concentrations calculated 
are for diluted samples and needs to be converted. 
 
 
 
 
y = 0.0009x + 0.0734 
R² = 0.9878 
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Example of protein concentration calculation:  
The sample absorbance minus background absorbance = 0,220. 
 
𝑥 =
(0,220 − 0,0734)
0,0009
 
𝑥 = 163,06 µ𝑔/𝑚𝐿 
 
Since the samples were diluted (5µL sample + 55µL lysisbuffer), the concentration of undiluted 
sample needed to be calculated using the formula below: 
  
C1*V1 = C2*V2 
       
C1= Concentration of undiluted sample 
 
  
V1= Volume of undiluted sample = 5µL   
C2= Concentration of diluted sample 
V2= End volume after dilution = 60µL   
          
 
𝐶1 =  
163,06 µ𝑔/𝑚𝐿 ∗ 60 µ𝐿
5 µ𝐿 
  
𝐶1 = 1956,7 µ𝑔/𝑚𝐿 
 
10 µg of sample was to be applied on the gel. Calculation of volume was done with the formula below 
where V = volume, m = mass and c = concentration: 
  
𝑉 =  
𝑚 [µ𝑔]
𝑐 [µ𝑔/𝑚𝐿]
 
𝑉 =  
10 µ𝑔
 1956,7 µ𝑔/𝑚𝐿
 
𝑉 =  0,00511 𝑚𝐿 = 5,11 µ𝐿 
 
The volume of sample to be applied to the gel (5,11 µL) was diluted with lysis buffer to a total volume 
of 10 µL. 
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VII) R&D-buffer, pH 7,5 
For 1 L R&D-buffer: 
 
25 mM Tris pH 7,5  = 25 mL 1M Tris 
0,15M NaCl  = 30 mL 5M NaCl 
0,1 % Tween  = 5 mL 20 % Tween 
   Fill with dH2O to 1 L 
 
VIII) Stripping solution   
For 1 L Stripping solution: 
 
7,5 g Glycine 
900 mL dH2O 
10 mL 12M HCl pH 2,2 (=37 %) 
Fill with dH2O to 1 L 
 
IX) PuMA-medium 
1x) Medium M199 (1x) 
Crystalline bovine insulin – 1 µg/mL 
Hydrocortisone – 0,1 µg/mL 
Retinyl acetate – 0.1 µg/mL 
Penicillin/Streptamycin – 10 µl/mL 
 
2x)  Medium M199 (2x) 
Crystalline bovine insulin – 2 µg/mL 
Hydrocortisone – 0,2 µg/mL 
Retinyl acetate – 0.2 µg/mL 
Penicillin/Streptamycin – 20 µl/mL 
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X) Supplementary data  
 
a) Combination therapy graphs presented as column charts 
 
b) Spheroid growth curves of all tested drug concentrations 
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c) Glo-graphs of all tested drug concentrations 
 
 
 
d) PuMA-quantification graphs including all tested drug concentrations 
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e) Combination therapy graphs related to DMSO-control cells 
 
 
